NETHERLANDS REFERENCE LABORATORY FOR BACTERIAL MENINGITIS

BACTERIAL MENINGITIS IN THE NETHERLANDS

ANNUAL REPORT 2020

Amsterdam UMC
University Medical Centers

BACTERIAL MENINGITIS IN THE NETHERLANDS
ANNUAL REPORT 2020

NETHERLANDS REFERENCE LABORATORY FOR BACTERIAL MENINGITIS

Amsterdam UMC, Academic Medical Center (AMC)
and
National Institute of Public Health and the Environment (RIVM),
Department of Medical Microbiology and Infection Prevention, AMC
PO Box 22660 , 1100 DD Amsterdam
The Netherlands
Telephone
+31 20 566 4874
+31 20 566 4864
E-mail: reflab@amsterdamumc.nl

Netherlands Reference Laboratory for Bacterial Meningitis (AMC/RIVM)
Bacterial meningitis in the Netherlands; annual report 2020
Amsterdam: University of Amsterdam, 2021

CONTENTS

1 INTRODUCTION

This is the **49th** Annual Report of the Netherlands Reference Laboratory for Bacterial Meningitis (NRLBM) of the Academic Medical Center (AMC) and the National Institute of Public Health and the Environment (RIVM). The NRLBM is located within the Department of Medical Microbiology and Infection Prevention of the Amsterdam UMC, location AMC in Amsterdam, The Netherlands. Nearly all Dutch clinical microbiology collaborate with the NRLBM by submitting bacterial isolates and/or cerebrospinal fluid samples from patients with meningitis as well as other invasive diseases and we are most grateful to our colleagues for their collaboration.

The NRLBM started collecting isolates of *Neisseria meningitidis* in 1959 and of other meningitis-causing bacteria in 1975.

In the archives of the NRLBM approximately 90,000 isolates are now available for studies on the epidemiology of bacterial meningitis and on the pathogenicity and antibiotic susceptibility of isolates.

The objectives of the NRLBM are:
- to perform surveillance of bacterial meningitis and other invasive bacterial infections;
- to describe the (molecular) epidemiology of bacterial meningitis and select invasive bacterial infections in the Netherlands;
- to provide insights and leads for the development of potential vaccine components;
- to provide data about antibiotic susceptibility of isolates.

The information is presented in tables and figures and shortly discussed in the text.

We welcome your opinion and suggestions on this report.

Amsterdam, May, 2021

N.M. van Sorge, PhD, Associate Professor | head of the NRLBM
dr. W. Freudenburg, medical microbiologist

2 ISOLATES, CSF SPECIMENS AND SERA RECEIVED

The Netherlands Reference Laboratory for Bacterial Meningitis (NRLBM) collects isolates from cerebrospinal fluid (CSF) and blood from patients with proven meningitis (CSF and possibly blood culture positive) or with bacteraemia and suspected meningitis (blood culture positive only). Unless otherwise indicated, every isolate from CSF, from CSF and blood and from blood represents a patient with meningitis, a patient with meningitis and bacteraemia, or a patient with bacteraemia, respectively. When CSF is noted as the isolation source, this could indicate an isolate or positive PCR from CSF or CSF and blood. Incidences have been calculated by dividing the number of annually-received isolates (in a particular patient age group) by the number of inhabitants (within that same age group) multiplied by 100,000. Population statistics were obtained from Statistics Netherlands[1] using StatLine. By estimation, the NRLBM receives about 90% of the isolates from bacterial meningitis patients in the Netherlands.



Figure 2.1. *Isolates and materials for PCR received by the NRLBM.*

[1] CBS - Statline Statistics Netherland www.cbs.nl

In 2020, the NRLBM received isolates from CSF and/or blood and CSF and/or serum samples wich were positive in antigen or PCR tests from 1,869 patients (**table 2.1/table 11.1**). Of all patients, 249 were culture or PCR confirmed cases of bacterial meningitis.

Table 2.1

	Number of specimens
Isolates (CSF and/or blood)	*1,844*
PCR or antigen positive samples of CSF, Sera and other fluids	*25*
Total positive isolates and PCR or antigen positive samples	**1,869**
PCR or antigen negative samples of CSF, Sera and other fluids	**74**
Total	**1,943**

In 2020, 49 clinical microbiology laboratories submitted isolates or samples to the NRLBM. Table 2.2 shows the received isolates or positive PCR samples from 1,869 patients according to species and to laboratory where cases were diagnosed. From 2003 onwards, the NRLBM requested nine sentinel laboratories, evenly distributed across the country and covering 25% of the Dutch population, to submit pneumococcal isolates from CSF and/or blood from patients of all ages.Those nine sentinel laboratories are marked in orange in table 2.2.

Table 2.2 Number of isolates or positive PCR samples from CSF and/or blood received in 2020, according to laboratory and bacterial species.

Location	Laboratory	Bacterial species[#]												
		Nm	Hi	Sp	Ec	Sag	Lm	Spy	Sau	Cns	Cn	Ot	Nv	Total
Alkmaar	MCA lab. Med. Microbiologie	2	7	25	3	4	-	-	2	-	-	1	-	**44**
Amersfoort	Meander Medisch Centrum	3	4	26	-	2	4	-	-	-	-	1	-	**40**
Amsterdam	Amsterdam UMC	1	9	36	13	6	2	11	5	4	-	13	-	**100**
	Onze Lieve Vrouwe Gasthuis	1	5	6	-	8	2	5	-	-	-	-	-	**27**
	Slotervaart / ATAL	-	2	9	-	2	2	-	-	-	-	1	-	**16**
Apeldoorn	Gelre Ziekenhuizen	-	4	33	-	2	3	1	-	-	-	1	-	**44**
Arnhem	Rijnstate	1	2	34	1	2	3	9	-	-	1	-	-	**53**
Breda	Amphia Ziekenhuis	1	6	23	3	4	1	3	1		1	-	-	**43**
Capelle ad IJssel	IJsselland Ziekenhuis	-	1	6	1	-	1	1	-	-	-	-	-	**10**
Delft	Reinier Haga MDC	-	4	9	-	2	2	-	-	-	-	-	-	**17**
Den Bosch	Regionaal laboratorium Den Bosch	2	6	38	1	2	2	1	-	-	-	1	-	**53**
Den Haag	Haga Ziekenhuis, loc. Leyenburg	2	7	24	-	6	1	1	-	-	-	-	-	**41**
	MA Haaglanden, loc Westeinde	3	3	20	1	-	1	-	-	-	-	-	-	**28**
Deventer	Deventer Ziekenhuis	2	3	19	-	1	4	1	-	-	-	-	-	**30**
Doetinchem	Slingeland Ziekenhuis	1	1	26	2	-	3	1	-	-	-	-	-	**34**
Dordrecht	RLM Dordrecht / Gorinchem	2	5	35	1	5	2	4	-	-	-	2	-	**56**
Ede	Gelderse Vallei	3	4	30	7	7	4	1	-	-	-	1	-	**57**
Goes	Lab. v. Med.Microb. & Imm., ADRZ	1	3	15	-	-	2	1	-	-	-	-	-	**22**
Gouda	Groene Hart Ziekenhuis	2	2	17	-	1	4	-	-	-	-	-	-	**26**
Groningen	Certe, Lab. v. Infectieziekten	3	9	52	1	4	3	-	-	-	-	1	-	**73**

Location	Laboratory	Bacterial species#												
		Nm	Hi	Sp	Ec	Sag	Lm	Spy	Sau	Cns	Cn	Ot	Nv	Total
	UMCG	3	-	6	3	1	1	3	-	-	-	-	-	**17**
Haarlem	Streeklab voor de Volksgezondheid	2	2	32	2	3	4	11	-	-	-	-	-	**56**
Harderwijk	St. Jansdal Ziekenhuis	1	5	19	-	2	2	2	-	-	-	-	-	**31**
Hengelo	LabMicTa	1	9	55	-	4	3	8	-	-	-	1	-	**81**
Hilversum	Centraal Bact. Ser. Lab.	2	-	5	-	1	1	1	-	-	-	2	-	**12**
Hoorn	Westfries gasthuis	-	8	30	2	3	-	-	-	-	1	-	-	**44**
Leeuwarden	Izore, centrum infectieziekten Friesland	5	5	57	2	6	2	20	-	-	-	3	-	**100**
Leiden	Alrijne ziekenhuis	-	6	21		2	1	1	-	-	-	1	-	**32**
	LUMC, KML, Lab.voor Bacteriologie	-	4	16	3	6	2	2	-	-	4	-	-	**37**
Maastricht	Acad. Ziekenhuis Maastricht	-	4	8	-	-	-	-	-	-	-	-	1	**13**
Nieuwegein	St. Antonius Ziekenhuis	-	7	35	-	-	3	7	-	-	-	1	-	**53**
Nijmegen	Canisius Wilhelmina Zknhs	-	5	25	-	1	-	-	-	-	-	-	-	**31**
	UMC St. Radboud	2	9	17	14	7	3	3	-	1	-	1	-	**57**
Neth Antilles	Medical Microbology, Curacao/St.Maarten	-	3	5	-	-	-	-	-	-	-	1	-	**9**
Roermond	St. Laurentius Ziekenhuis	-	1	1	-	-	1	-	-	-	1	-	-	**4**
Roosendaal	St. Fransiscus Ziekenhuis	1	2	15	1	4	1	1	-	-	-	1	-	**26**
Rotterdam	Erasmus MC Med. Microbiologie	2	8	29	12	4	-	-	-	-	-	-	-	**55**
	Ikazia Ziekenhuis	1	1	7	1	2	1	-	-	-	-	-	-	**13**
	Maasstad Ziekenhuis	1	3	19	2	-	1	-	-	-	-	-	-	**26**
	St.Franciscus Gasthuis	2	5	21	4	3	-	-	-	-	-	-	-	**35**
Sittard	Zuyderland Medisch Centrum	2	3	44	-	3	2	-	-	-	1	-	-	**55**
Terneuzen	MICROVIDA, location Terneuzen	-	1	9	-	-	2	-	-	-	-	-	-	**12**
Tilburg	Streeklab. Tilburg	-	3	33	1	4	1	-	-	-	2	1	-	**45**
Utrecht	Diakonessenhuis	2	1	2	-	-	1	3	-	-	-	-	-	**9**
	St. Antonius	-	-	1	-	-	-	1	-	-	-	-	-	**2**
	UMC Med. Microbiologie	2	2	12	8	5	1	-	2	-	-	1	-	**33**
Veldhoven	PAMM, Lab. Med. Microbiologie	3	10	56	2	8	2	6	-	-	-	-	-	**87**
Venlo	Vie Curie medisch centrum	1	-	-	-	-	-	1	-	-	-	-	-	**2**
Zwolle	Isala Klinieken LMMI	3	8	52	3	2	-	7	-	-	-	3	-	**78**
Total		**66**	**202**	**1115**	**94**	**129**	**81**	**117**	**10**	**5**	**11**	**41**	**1**	**1869**

Nm: *N. meningitidis*; **Hi:** *H. influenzae*; **Sp:** *S. pneumoniae*; **Ec:** *E. coli*; **Sag:** *S. agalactiae*; **Lm:** *L. monocytogenes*; **Spy:** *S.pyogenes*; **Sau:** *S. aureus*; **Cns:** Coagulase-negative staphylococci; **Cn:** *C. neoformans;* **ot:** other bacteria; nv: non viable.

The distribution of the received isolates over the 5-year period 2016 - 2020 is presented in table 2.3. The total number of isolates increased from 1,490 in 2016 to 2,685 in 2019 (mainly due to changed submission criteria), which decreased to 1,869 isolates (~30%) in 2020. This decrease is likely attributable to the introduction of containment policies that were implemented in response to the COVID-19 pandemic. The decrease was particularly impressive for *N. meningitidis*, which decreased from 157 isolates in 2019 to 66 isolates in 2020 (58%) and *S. pneumoniae*, with 678 fewer isolates in 2020 (38%). In contrast, the number of *H. influenzae* isolates only showed a 10% decrease, despite the fact that hthis pathogen is also transmitted via respiratory droplets. Also for neonatal pathogens, *E. coli* and *S. agalactiae*, no effect of the COVID-19 containment measures was observed compared to the previous year.

Table 2.3 Number of isolates from CSF and/or blood received in the years 2016 – 2020

Species	2016			2017			2018			2019			2020		
	CSF	Blood	Total	CSF	Blood	Total	CSF	Blood	Total	CSF	Blood	Total	CSF	Blood	Total
***N. meningitidis*[1]**	36	100	136	67	134	201	70	135	205	53	104	157	27	39	66
H. influenzae	26	162	188	30	194	224	23	216	239	23	203	226	21	181	202
S. pneumoniae	143	762	905	148	1255	1403	152	1757	1909	165	1628[2]	1793	108	1007	1115
E. coli	18	32	50	8	41	49	12	50	62	18	78	96	19	75	94
S. agalactiae	20	49	69	24	63	87	27	79	106	23	97	120	22	107	129
L. monocytogenes	11	59	70	20	71	91	9	56	65	26	81	107	11	70	81
S. pyogenes	5	5	10	7	11	18	3	9	12	14	122	136	5	112	117
S. aureus	10	1	11	5	0	5	7	0	7	11	0	11	10	0	10
Coag.neg.Staph.	2	0	2	6	0	6	4	0	4	2	0	2	4	1	5
C. neoformans	7	3	10	7	2	9	8	5	13	8	2	10	6	5	11
others	19	18	37	9	13	22	18	7	25	16	11	27	16	22	38
non viable	0	2	2	0	3	3	0	7	7	0	0	0	0	1	1
Total	**297**	**1193**	**1490**	**331**	**1787**	**2118**	**333**	**2321**	**2654**	**359**	**2326**	**2685**	**249**	**1620**	**1869**

[1]Including PCR positive patients
[2] 345 (2020) blood isolates from 9 sentinel labs
CSF: CSF or CSF and blood
blood: blood only

The incidence of invasive bacterial infections of the different bacterial species over the years 2016 to 2020 is shown in table 2.4. Incidences follow the number of received isolates/samples, i.e. incidence of *N. meningitidis* and *S. pneumoniae* decreased substantially from 2019-2020, whereas the incidence for *H. influenzae*, *E. coli* and *S. agalactiae* invasive disease remained fairly similar.

Table 2.4 Incidence of invasive bacterial infections per species per 100,000 inhabitants, 2016 - 2020

Species	2016	2017	2018	2019	2020
N. meningitidis	0.80	1.18	1.19	0.91	0.38
H. influenzae	1.11	1.31	1.39	1.31	1.16
S. pneumoniae	5.33	8.21	11.11	10.37	6.41
E. coli	0.29	0.29	0.36	0.56	0.54
S. agalactiae	0.41	0.51	0.62	0.69	0.74
L. monocytogenes	0.41	0.53	0.38	0.62	0.47
S. pyogenes	0.06	0.11	0.07	0.79	0.67
S. aureus	0.07	0.03	0.04	0.06	0.06
Coag. neg. Staph.	0.01	0.04	0.02	0.01	0.03
C. neoformans	0.06	0.05	0.08	0.06	0.06
others	0.22	0.13	0.15	0.16	0.22
non viable	0.01	0.02	0.04	-	0.01
Total	**8.78**	**12.40**	**15.45**	**15.54**	**10.74**

Table 2.5 shows the distribution of isolates according to the source from which they were cultured. The top five species are comprised by *S. pneumoniae*, *H. influenzae, S. agalactiae, S. pyogenes, and E. coli*.

Table 2.5 Total number of isolates from CSF and/or blood received in 2020, according to bacterial species and source.

Species		CSF or CSF and blood, n	Blood only, n	Total, n	%
Neisseria meningitidis		27	39	66	**3.5**
Haemophilus influenzae [1, 2]		21	181	202	**10.8**
Streptococcus pneumoniae		108	1007	1115	**59.7**
Escherichia coli [3]		19	75	94	**5.0**
Streptococcus agalactiae		22	107	129	**6.9**
Listeria monocytogenes		11	70	81	**4.3**
Streptococcus pyogenes		5	112	117	**6.3**
Staphylococcus aureus		10	0	10	**0.5**
Coagulase-negative staphylococcus [4]		4	1	5	**0.3**
Cryptococcus neoformans[5]		6	5	11	**0.6**
Others total		16	22	38	**2.0**
Others	*Klebsiella pneumoniae*	*1*	*0*	*1*	
	Pseudomonas aeruginosa	*1*	*0*	*1*	
	Citrobacter koseri	*1*	*0*	*1*	
	Enterobacter cloacae	*2*	*0*	*2*	
	Listeria innocua	*0*	*1*	*1*	
	Haemophilus parainfluenzae	*0*	*3*	*3*	
	Neisseria subflava	*0*	*1*	*1*	
	Streptococcus dysgalactiae ssp equisimilis	*2*	*5*	*7*	
	Streptococcus gallolyticus ssp gallolyticus	*0*	*2*	*2*	
	Streptococcus gallolyticus ssp pasteurianus	*1*	*1*	*2*	
	Streptococcus infantis	*1*	*0*	*1*	
	Streptococcus intermedius	*1*	*0*	*1*	
	Streptococcus mitis[6]	*1*	*5*	*6*	
	Streptococcus oralis subsp.oralis	*1*	*1*	*2*	
	Streptococcus parasanguinis	*0*	*1*	*1*	
	Streptococcus pseudopneumoniae	*0*	*1*	*1*	
	Streptococcus salivarius	*1*	*0*	*1*	
	Enterococcus faecalis	*1*	*0*	*1*	
	Capnocytofaga canimorsus	*0*	*1*	*1*	
	Raoultella ornithinolytica	*1*	*0*	*1*	
	Rothia mucilaginosa	*1*	*0*	*1*	
Non viable		0	1	1	**0.1**
Total		249	1620	1869	**100.0**

1 In five patients ***Haemophilus influenzae*** and ***Streptococcus pneumoniae*** were isolated from blood.

2 In one patient ***Haemophilus influenzae*** and ***Streptococcus pyogenes*** were isolated from blood.

3 In one patient ***Escherichia coli, Staphylococcus epidermidis*** and ***Streptococcus agalactiae*** were isolated from blood (0 months of age)

4 Coagulase-negative staphylococci, 2 ***Staphylococcus epidermidis*** were isolated from CSF and one from blood; one***Staphylococcus haemolyticus*** and one ***Staphylococcus capitis*** were isolated from CSF

5 From the 5 Cryptococcus isolates from blood, 2 were ***C. neoformans***, 2 ***C. deneoformans*** and one ***C. species***

6 In one patient ***Streptococcus mitis*** and ***Streptococcus parasanguis*** were isolated from blood

3 BACTERIAL MENINGITIS – general overview

In 2020, the NRLBM received CSF isolates or PCR-positive CSF samples from 249 patients (Table 2.3 and 11.1). The proportion of meningococcal, pneumococcal, and haemophilus cases among meningitis patients was 11%, 43%, and 8%, respectively (Figure 3.1). The neonatal pathogens *S. agalactiae* and *E. coli* represented 9% and 8% of the meningitis cases, respectively (Figure 3.1)



Figure 3.1 *Proportional distribution of CSF isolates and CSF positive samples according to bacterial species, 2020*

Figure 3.2 shows the total annual number of bacterial isolates from CSF during the period 1990-2020. The 30-year trend line shows a decrease over the last three decades. The incidence per 100,000 inhabitants has stabilized around 2.0 (range 1.8 – 1.4) from approximately 2010 until now (Figure 3.2).
Bacterial meningitis cases over the same 30-year period according to specific species, i.e. *N. meningitidis, H. influenzae* and *S. pneumoniae*, are presented in figure 3.3. Comparing meningitis incidence pre- and post-vaccination, the incidence of *Haemophilus* meningitis decreased from 1.6 per 100,000 in 1992 to 0.12 per 100,000 in 2020 and has remained at this

low level. For meningococcal meningitis, the incidence decreased from 3.1/100,000 in 1993 to 0.16/100,000 in 2020, mainly due to a decline in the number of cases caused by serogroups B, C and W meningococci. The decline in serogroup C meningococcal meningitis is largely attributed to nationwide vaccination, which started in 2002 and immediate showed a decrease in 2003. After an increase in meningococcal meningitis between 2016 and 2018 as a result of MenW, the number of of meningococcal meningitis cases decreased again to 27 in 2020. This is likely the result of two events; the introduction of the MenACWY vaccine in the National Immunisation Programme as of 1 May 2018 and the COVID-19 containment measures in 2020. Pneumococcal meningitis showed a slight increase in annual incidence between 1991 and 2004 from 1.0 to 1.6 per 100,000 inhabitants. The introduction of the 10-valent conjugated polysaccharide vaccine (PCV-10) against pneumococci for children in the National Immunisation Programme in June 2006 decreased the incidence of pneumococcal meningitis to 0.95 per 100,000 in 2019. In 2020, the incidence of pneumococcal meningitis further decreased to 0.62 per 100,000 inhabitants, likely as a result of COVID-19 containment measures.



Figure 3.2 *All cause meningitis cases and incidence, 1990-2020*



Figure 3.3 Number of cases and incidence of *meningococcal, haemophilus and pneumococcal meningitis (isolates and/or positive PCR from CSF), 1990-2020*

Table 3.1 shows the number of CSF isolates by annual quarter grouped per bacterial species. As in previous years, most isolates were received during the first quarter of the year.

Table 3.1 Isolates and PCR-positive samples from CSF by annual quarter according to bacterial species, 2020

	ANNUAL QUARTER					
SPECIES	**First**	**Second**	**Third**	**Fourth**	**Total**	**%**
N. meningitidis	14	4	5	4	**27**	*10.9*
H. influenzae	6	1	6	8	**21**	*8.5*
S. pneumoniae	50	15	22	21	**108**	*43.4*
E. coli	3	4	5	7	**19**	*7.6*
S. agalactiae	9	2	8	3	**22**	*8.8*
L. monocytogenes	4	0	6	1	**11**	*4.4*
S. pyogenes	4	0	0	1	**5**	*2.0*
S. aureus	0	5	2	3	**10**	*4.0*
Coag.neg.Staph.	2	2	0	0	**4**	*1.6*
C. neoformans	1	3	1	1	**6**	*2.4*
Others	4	4	5	3	**16**	*6.4*
non viable	0	0	0	0	**0**	*0.0*
Total	**97**	**40**	**60**	**52**	**249**	*10.9*
%	***38.9***	***16.1***	***24.1***	***20.9***	***100.0***	

Tables 3.2 and 3.3 show the distribution of bacterial species isolated from CSF according to patient age and the age-specific incidence per 100,000 persons, respectively. *S. agalactiae* and *E. coli* are still the predominant species isolated from neonates (i.e. younger than 1 month), and together represented 81% of all isolates in this age group. In contrast, in infants 1-11 months of age, the predominant species were *H. influenzae* and *S. pneumoniae* (together 61%). Since the introduction of the *H. influenzae* b vaccine in 1993, the number of *H. influenzae* b meningitis cases in the age group 0-4 year has strongly decreased, from 231 in 1992 to 9 in 2020. Overall, for children ages 0-4 years *S. agalactiae* was the predominant cause of bacterial meningitis, representing 25% of all cases in this age group

Table 3.2 Isolates and PCR-positive samples from CSF grouped according to patients' age, 2020

	AGE (MONTHS)			AGE (YEARS)									TOTAL	
Group	**0**	**1-11**	**12-59**	**0-4**	**5-9**	**10-14**	**15-19**	**20-29**	**30-39**	**40-49**	**50-64**	**65-79**	**≥80**	**Total, n**	**%**
N. meningitidis	0	3	4	7	3	0	6	4	0	2	3	2	0	**27**	***10.9***
H. influenzae	0	8	6	14	0	0	1	1	0	0	1	4	0	**21**	***8.5***
S. pneumoniae	0	6	3	9	3	1	0	0	8	16	32	37	2	**108**	***43.4***
E. coli	12	2	1	15	0	0	0	0	0	0	3	0	1	**19**	***7.6***
S. agalactiae	17	2	1	20	0	0	0	0	0	0	1	1	0	**22**	***8.8***
L. monocytogenes	0	0	0	0	0	0	0	0	0	2	0	3	6	**11**	***4.4***
S. pyogenes	0	0	2	2	1	0	0	0	1	0	1	0	0	**5**	***2.0***
S. aureus	3	0	0	3	1	0	2	0	0	2	1	1	0	**10**	***4.0***
Coag.neg.Staph.	1	2	0	3	0	0	0	0	0	0	0	1	0	**4**	***1.6***
C. neoformans	0	0	0	0	0	0	0	1	1	0	1	3	0	**6**	***2.4***
Others	3	0	2	5	0	0	1	1	2	4	0	2	1	**16**	***6.4***
non viable	0	0	0	0	0	0	0	0	0	0	0	0	0	**0**	***0.0***
Total, n	*36*	*23*	*19*	*78*	*8*	*1*	*10*	*7*	*12*	*26*	*43*	*54*	*10*	**249**	***100***
%	***14.5***	***9.2***	***7.6***	***31.3***	***3.3***	***0.4***	***4.0***	***2.8***	***4.8***	***10.4***	***17.3***	***21.7***	***4.0***	***100***	

As anticipated from table 3.2, the incidence of all-cause bacterial meningitis was highest in the 0-11 month age group (table 3.3) with 35.8 cases per 100,000. Overall, the incidence of bacterial meningitis decreased from 2.08 in 2019 to 1.43 per 100,000 in 2020.

Table 3.3 Age-specific incidence of bacterial meningitis per 100,000 inhabitants according to bacterial species, 2020

	AGE (YEARS)										
SPECIES	**0**	**1-4**	**5-9**	**10-14**	**15-19**	**20-29**	**30-39**	**40-49**	**50-64**	**65-79**	**≥80**	Total
N. meningitidis	1.77	0.58	0.33	-	0.57	0.18	-	0.09	0.08	0.08	-	0.16
H. influenzae	4.72	0.87	-	-	0.10	0.04	-	-	0.03	0.16	-	0.12
S. pneumoniae	3.54	0.43	0.33	0.10	-	-	0.37	0.72	0.88	1.44	0.24	0.62
E. coli	8.26	0.14	-	-	-	-	-	-	0.08	-	0.12	0.11
S. agalactiae	11.21	0.14	-	-	-	-	-	-	0.03	0.04	-	0.13
L. monocytogenes	-	-	-	-	-	-	-	0.09	-	0.12	0.71	0.06
S. pyogenes	-	0.29	0.11	-	-	-	0.05	-	0.03	-	-	0.03
S. aureus	1.77	-	0.11	-	0.19	-	-	0.09	0.03	0.04	-	0.06
Coag.neg.Staph.	1.77	-	-	-	-	-	-	-	-	0.04	-	0.02
C. neoformans	-	-	-	-	-	0.04	0.05	-	0.03	0.12	-	0.03
Others	-	0.29	-	-	0.10	0.04	0.09	0.18	-	0.08	0.12	0.09
non viable	-	-	-	-	-	-	-	-	-	-	-	-
Total	**34.81**	**2.75**	**0.88**	**0.10**	**0.95**	**0.31**	**0.56**	**1.18**	**1.18**	**2.10**	**1.18**	**1.43**

Table 3.4 shows the number of CSF isolates per species according to patient gender. For most species the Male/Female ratio varied between 1 and 2, except for *E. coli* and *S. aureus*, which affected males more than twice as often as females. The overall M/F ratio was 1.3.

Table 3.4 Isolates and PCR positive samples from CSF according to patients' gender, 2020

SPECIES	M	F	M/F – ratio	Sex not known	Total	%
N. meningitidis	16	9	**1.8**	2	**27**	*10.9*
H. influenzae	14	7	**2**	-	**21**	*8.5*
S. pneumoniae	58	49	**1.2**	1	**108**	*43.4*
E. coli	13	6	**2.2**	-	**19**	*7.6*
S. agalactiae	11	9	**1.2**	2	**22**	*8.8*
L. monocytogenes	4	7	**0.6**	-	**11**	*4.4*
S. pyogenes	3	2	**1.5**	-	**5**	*2.0*
S. aureus	7	3	**2.3**	-	**10**	*4.0*
Coag.neg.Staph.	1	3	**0.3**	-	**4**	*1.6*
C. neoformans	3	3	**1.0**	-	**6**	*2.4*
Others	8	7	**1.1**	1	**16**	*6.4*
non viable	0	0	**-**	-	**0**	*0.0*
Total	**138**	**105**	**1.3**	**6**	**249**	*100*
%	***55.4***	***42.2***		***2.4***	***100***	

4 NEISSERIA MENINGITIDIS

4.1 General features

In 2020, the NRLBM received 54 *Neisseria meningitidis* isolates of which 15 were isolated from CSF (or CSF and blood; 33 in 2019) and 39 from blood only (102 in 2019). In addition, 12 culture-negative CSF samples tested positive for meningococci by PCR. In total, we received meningococcal isolates or PCR-positive CSF or blood from 66 patients. The distribution of isolates received throughout the year was different from previous years in that the number of isolates decreased greatly in the second quarter and remained low throughout the year (figure 4.1).



Figure 4.1 *Seasonal distribution of meningococcal disease, 2010-2020*

4.2 Antibiotic susceptibility

Seventy-eight percent of all isolates (42/54) were susceptible to penicillin (MIC ≤ 0.064 µg/ml) and one isolate was resistant to penicillin (MIC > 0.25 µg/ml; Table 4.1). The proportion of penicillin susceptible and penicillin intermediate isolates was similar for isolates from blood and CSF (Tables 4.2, 4.3). In general, mutations in *penA,* encoding a penicillin binding protein, confer meningococcl with reduced penicillin susceptibility. All isolates were susceptible to Rifampicine.

Table 4.1 Penicillin susceptibility [2]of all received *N. meningitidis* isolates according to source of isolation (CSF and/or blood), 2020

	Penicillin*				
	MIC ≤ 0.064 (S)	**0.064< MIC≤0.25 (I)**	**MIC>0.25 (R)**	**Total**	**%**
CSF or CSF and blood	10	4	1	**15**	***28***
Blood only	32	7	0	**39**	***72***
Total	**42**	**11**	**1**	**54**	***100***
%	***78***	***20***	***2***	***100***	

* MIC values in µg/ml

Table 4.2 Penicillin susceptibility of *N. meningitidis* isolates from CSF, 2016-2020

	Penicillin*						
	MIC ≤ 0.064 (S)		**0.064< MIC≤0.25 (I)**		**MIC>0.25 (R)**		**Total**
	N	%	N	%	N	%	N
2016	32	*88.0*	4	*12.0*	0	*0.0*	**36**
2017	37	*80.4*	9	*19.6*	0	*0.0*	**46**
2018	39	*72.2*	14	*25.9*	1	*1.9*	**54**
2019	31	*93.9*	2	*6.1*	0	*0.0*	**33**
2020	10	*66.7*	4	*26.7*	1	*6.6*	**15**

* MIC values in µg/ml

Table 4.3 Penicillin susceptibility of *N. meningitidis* isolates from blood only, 2016-2020

	Penicillin*						
	MIC ≤ 0.064 (S)		**0.064< MIC≤0.25 (I)**		**MIC>0.25 (R)**		**Total**
	N	%	N	%	N	%	
2016	88	*88.0*	12	*12.0*	0	*0.0*	**100**
2017	104	*80.6*	24	*18.6*	1	*0.8*	**129**
2018	99	*75.6*	30	*22.9*	2	*1.5*	**131**
2019	97	*95.1*	5	*4.9*	0	*0.0*	**102**
2020	32	*82.1*	7	*17.9*	0	*0.0*	**39**

* MIC values in µg/ml

[2] According to Eucast: https://eucast.org/clinical_breakpoints/

4.3 Serogroups

Serogroup B accounted for 61% of all received isolates (Table 4.4), which is an increase compared to previous years (2019 46%; 2018: 36%;). However, observations across the entire collection period 1959 - 2019 (figure 4.2) show that the number of serogroup B isolates in 2020 was the lowest (40 cases) in 60 years. The proportion of serogroup W isolates decreased to 18% (table 4.4) compared to 38% in 2019; 50% in 2018, 41% in 2017, 34% in 2016 and 10% in 2015. Also in absolute numbers, the NRLBM received less serogroup W isolates (n = 12) compared to the previous 3 years (Figure 4.8). This reduction in meningococcal W cases is likely resulting from the implementation of the MenACWY vaccine in the National Immunisation Programme as of 1 May 2018 as well as the COVID-19 containment measures in 2020. Because meningococcal serogroup W also affects older children and because meningococcal carriage is highest in this agegroup, the vaccination has also been offered to teenagers in the year of their 14th birthday, as of 1 October 2018. The MenACWY vaccine was introduced to the vaccination program to counter an increase in the number of meningococcal W cases between 2016-2018 and replaced the MenC vaccine.

Serogroup Y was responsible for 13.6% of all cases of invasive meningococcal disease in 2020 (Table 4.4). In 2020, no serogroup C was isolated from CSF or blood, which has not been observed in the past 60 years of surveillance by the NRLBM. Both the proportion as well as absolute number of serogroup C isolates increased between 1991 and 2001 from approximately 10% in 1994 (66 cases) to 19% (105 cases) in 2000 and 40% (276 cases) in 2001 (figure 4.2). In response, vaccination against serogroup C was included in the National Immunisation Program in June 2002, resulting in a rapid decline and near eradication of disease caused by serogroup C meningococci. Overall, serogroups B and W have the highest incidence of invasive meningococcal disease (Table 4.5). Cases of invasive meningococcal disease are evenly distributed across the Netherlands (Figure 4.3).

Table 4.4 Number of meningococcal isolates according to serogroup and source of isolation, 2020

Source	Serogroup						Total, n
	B	W	E	X	Y	NG	
CSF	*24*	*2*	*0*	*0*	*0*	*1*	*27*
Blood	*16*	*10*	*1*	*2*	*9*	*1*	*39*
Total (%)	**40 (60.7)**	**12 (18.2)**	**1 (1.5)**	**2 (3.0)**	**9 (13.6)**	**2 (3.0)**	**66**

Table 4.5 Incidence of meningococcemia per 100,000 inhabitants according to serogroup and source of isolation, 2020

Source	Serogroup						Total
	B	W	E	X	Y	NG	
CSF	*0.14*	*0.01*	*0.00*	*0.00*	*0.00*	*0.01*	*0.16*
Blood	*0.09*	*0.06*	*0.01*	*0.01*	*0.05*	*0.01*	*0.22*
Total	**0.23**	**0.07**	**0.01**	**0.01**	**0.05**	**0.01**	**0.38**



Figure 4.2. *Distribution of meningococcal serogroups A, B, C and W across the entire collection period from 1959-2020.*



Figure 4.3 Geographical distribution of *N. meningitidis* cases based on incidence, *2020*. Incidence is calculated per municipality based on patient's place of residence.

4.4 Serogroup and age

Almost 21.5% (14 of 66) of patients with meningitis and/or meningococcemia was below the age of 5 (table 4.6). Among serogroup B cases, 68% (27/40) were between 0 and 25 years of age (table 4.6). In contrast, 67% (8/12) of the serogroup W cases were older than 50 years of age. In addition, 60% of serogroup B isolates (24/40) were from CSF, compared to only 16% (2/12) of serogroup W isolates, suggesting that the clinical presentation and population at risk for infection may be different for serogroup B and W meningococci. Of 39 patients from whom meningococci were isolated from blood only, 7 (18%) were younger than 5 years of age, while 14 (36%) were older than 65 years of age (table 4.7). Overall, the incidence of invasive meningococcal disease is highest in the age groups 0-4 and 15-19 with predominant contribution of serogroups B and W (table 4.7). Currently, the available menB vaccines (Bexsero and Trumemba) are not included in the National Immunisation Programme.[3]

Table 4.6 Serogroups of *N. meningitidis* (isolates or PCR-positive samples from CSF and /or blood; absolute numbers) according to patient's age, 2020

	AGE (MONTHS)			AGE (YEARS)									TOTAL	
Group	**0**	**1-11**	**12-59**	**0-4**	**5-9**	**10-14**	**15-19**	**20-24**	**25-29**	**30-49**	**50-64**	**≥65**	**n**	**%**
B	0	3	8	11	3	0	8	5	1	2	3	7	**40**	***60.7***
CSF	*0*	*2*	*4*	*6*	*3*	*0*	*6*	*3*	*1*	*1*	*3*	*1*	***24***	
Blood	*0*	*1*	*4*	*5*	*0*	*0*	*2*	*2*	*0*	*1*	*0*	*6*	***16***	
W	0	1	1	2	1	0	0	0	0	1	3	5	**12**	***18.2***
CSF	*0*	*1*	*0*	*1*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*1*	***2***	
Blood	*0*	*0*	*1*	*1*	*1*	*0*	*0*	*0*	*0*	*1*	*3*	*4*	***10***	
Y	1	0	0	1	0	0	0	0	1	1	2	4	**9**	***13.6***
CSF	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	***0***	
Blood	*1*	*0*	*0*	*1*	*0*	*0*	*0*	*0*	*1*	*1*	*2*	*4*	***9***	
E	0	0	0	0	0	0	0	0	0	0	1	0	**1**	***1.5***
CSF	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	***0***	
Blood	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*1*	*0*	***1***	
X	0	0	0	0	0	0	1	0	0	0	1	0	**2**	***3.0***
CSF	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	***0***	
Blood	*0*	*0*	*0*	*0*	*0*	*0*	*1*	*0*	*0*	*0*	*1*	*0*	***2***	
NG*	0	0	0	0	0	0	0	0	0	2	0	0	**2**	***3.0***
CSF	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*1*	*0*	*0*	***1***	
Blood	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*1*	*0*	*0*	***1***	
Total	**1**	**4**	**9**	**14**	**4**	**0**	**9**	**5**	**2**	**6**	**10**	**16**	**66**	***100.0***
CSF	***0***	***3***	***4***	***7***	***3***	***0***	***6***	***3***	***1***	***2***	***3***	***2***	***27***	
Blood	***1***	***1***	***5***	***7***	***1***	***0***	***3***	***2***	***1***	***4***	***7***	***14***	***39***	
%	***1.5***	***6.1***	***13.6***	***21.2***	***6.1***	***0.0***	***13.6***	***7.6***	***3.0***	***9.1***	***15.2***	***24.2***	***100.0***	

*Non Groupable

[3] Gezondheidsraad. Vaccinatie tegen meningokokken. Den Haag: Gezondheidsraad, 2018; publicatienr. 2018/28

Table 4.7 Incidence of meningococcemia per 100,000 inhabitants according to different serogroups of *N. meningitidis* and patient's age, 2020

	AGE (YEARS)										TOTAL
Group	**0**	**1-4**	**5-9**	**10-14**	**15-19**	**20-24**	**25-29**	**30-49**	**50-64**	**≥65**	
B	1.77	1.16	0.33	0.00	0.76	0.46	0.09	0.05	0.08	0.21	**0.23**
CSF	*1.18*	*0.58*	*0.33*	*0.00*	*0.57*	*0.27*	*0.09*	*0.02*	*0.08*	*0.03*	***0.14***
Blood	*0.59*	*0.58*	*0.00*	*0.00*	*0.19*	*0.18*	*0.00*	*0.02*	*0.00*	*0.18*	***0.09***
W	0.59	0.14	0.11	0.00	0.00	0.00	0.00	0.02	0.05	0.15	**0.07**
CSF	*0.59*	*0.00*	*0.00*	*0.00*	*0.00*	*0.00*	*0.00*	*0.00*	*0.00*	*0.03*	***0.01***
Blood	*0.00*	*0.14*	*0.11*	*0.00*	*0.00*	*0.00*	*0.00*	*0.02*	*0.08*	*0.12*	***0.06***
Y	0.59	0.00	0.00	0.00	0.00	0.00	0.09	0.02	0.05	0.12	**0.05**
CSF	*0.00*	*0.00*	*0.00*	*0.00*	*0.00*	*0.00*	*0.00*	*0.00*	*0.00*	*0.00*	***0.00***
Blood	*0.59*	*0.00*	*0.00*	*0.00*	*0.00*	*0.00*	*0.09*	*0.02*	*0.05*	*0.12*	***0.05***
E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.03	0.00	**0.01**
CSF	*0.00*	*0.00*	*0.00*	*0.00*	*0.00*	*0.00*	*0.00*	*0.00*	*0.00*	*0.00*	***0.00***
Blood	*0.00*	*0.00*	*0.00*	*0.00*	*0.00*	*0.00*	*0.00*	*0.00*	*0.03*	*0.00*	***0.01***
X	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.03	0.00	**0.01**
CSF	*0.00*	*0.00*	*0.00*	*0.00*	*0.00*	*0.00*	*0.00*	*0.00*	*0.00*	*0.00*	***0.00***
Blood	*0.00*	*0.00*	*0.00*	*0.00*	*0.01*	*0.00*	*0.00*	*0.00*	*0.03*	*0.00*	***0.01***
NG*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.00	0.00	**0.01**
CSF	*0.00*	*0.00*	*0.00*	*0.00*	*0.00*	*0.00*	*0.00*	*0.02*	*0.0*	*0.00*	***0.01***
Blood	*0.00*	*0.00*	*0.00*	*0.00*	*0.00*	*0.00*	*0.00*	*0.02*	*0.00*	*0.00*	***0.01***
Total	**2.95**	**1.30**	**0.44**	**0.00**	**0.86**	**0.46**	**0.18**	**0.14**	**0.27**	**0.47**	**0.38**
CSF	***1.77***	***0.58***	***0.33***	***0.00***	***0.57***	***0.27***	***0.09***	***0.05***	***0.08***	***0.06***	***0.16***
Blood	***1.18***	***0.72***	***0.11***	***0.00***	***0.29***	***0.18***	***0.09***	***0.09***	***0.19***	***0.41***	***0.22***

*Non Groupable

Figure 4.5 shows the age distribution of meningococcal disease caused by serogroups B and W. The age-specific incidence for serogroup B per 100,000 inhabitants in the age groups younger than 5 years and 15 - 19 years were 1.3 and 0.8, respectively (Figure 4.5B and Table 4.7). The age-specific incidence per 100,000 inhabitants for all age groups >19 years was below 0.5 (Table 4.7, Figure 4.5B). The age-specific incidence for serogroup W shows a different distribution compared to serogroup B (Figure 4.5B), with highest incidences for the age groups 0-5 years (0.2) and ages 65-69 years (0.4).



Figure 4.5 *A) Number of isolates and B) incidence of meningococcal disease* per 100,000 inhabitants *caused by serogroup B and W according to age groups, 2020*

4.5 Distribution of PorA and FetA genosubtypes among meningococci

4.5.1 PorA

In addition to serogrouping, meningococci can be further subtyped based on the variation in PorA and FetA proteins. Previously, subtyping was performed using specific monoclonal antibodies for these proteins. However, from January 1, 2005, the NRLBM subtypes meningococcal isolates by molecular methods, i.e. DNA-sequencing of PorA and FetA DNA coding regions, due to discontinuation of the monoclonal antibodies.

The PorA epitopes that react with the monoclonal antibodies of the subtyping scheme are encoded by the *porA* variable regions VR1 and VR2. Since 2000, we routinely sequence the DNA regions which encode the VR1 and VR2 regions of PorA of all meningococcal isolates. The DNA sequences are translated into putative amino acid sequences and are then compared with PorA epitopes present in the database available on the website: https://pubmlst.org/neisseria/PorA/ (PubMLST – PorA typing[4])(PubMLST - PorA typing, sd). As an example for a PorA notation, (VR1,VR2): P1.7,4, in which VR1 is P1.7 indicates the VR1 region and the second P1.4 indicates the VR2 region, resulting in the combination P1.7,4.

In 2020, the NRLBM received 12 PCR-positive samples of which six were completely subtyped. Overall, twenty-five different VR1/VR2 combinations were encountered among 40 serogroup B meningococci (2019: 30 different combinations; 2018: 37 different combinations). The proportion of dominant PorA genosubtypes has shifted tremendously in the last two decades: in 2000, genosubtype P1.7-2.4 represented 40% of all serogroup B isolates and gradually declined to only 10% in 2020 (table 4.8). Approximately 88% (35/40 isolates) of the serogroup B isolates had at least one of the PorA epitopes present in the NonaMen vaccine currently in development (Table 4.8), which is the highest hypothetical vaccine coverage in the past 5 years (Table 4.8).
Of twelve serogroup W isolates, 11 showed VR1/VR2 combination of PorA P1.5.2 (92%;Figure 4.6)



	P1.5,2	P1.5-1,xx	P1.5-2,xx	P1.7-1,1	P1.7-2,xx	P1.18-1,xx	P1.22,xx	Other
B		1	2	1	9	2	9	16
Y		4	5					
W	11							1
E	1							
X								2
NG		1						1

Figure 4.6 *Distribution of PorA genosubtypes among all received meningococcal isolates, 2020*

[4] *PubMLST - PorA typing*. Public databases for molecular typing: https://pubmlst.org/neisseria/PorA/

Table 4.8 PorA genosubtype distribution of *N. meningitidis* serogroup B isolates from 2016-2020

	VR1.VR2 combination	YEAR									
		2016		2017		2018		2019		2020	
		No.	%	No.	%	No.	%	No.	%	No.	%
Vaccine types*	1.5-1, 2-2	1	**1.5**	1	**1.4**	0	**0.0**	0	**0.0**	1	**2.5**
	1.5-1, other	2	**3.0**	3	**4.2**	2	**2.7**	0	**0.0**	0	**0.0**
	1.5-2.10	3	**4.4**	2	**2.9**	0	**0.0**	1	**1.4**	0	**0.0**
	1.5-2, other	1	**1.5**	2	**2.9**	1	**1.3**	0	**0.0**	2	**5.0**
	1.7,16	2	**3.0**	1	**1.4**	1	**1.3**	1	**1.4**	1	**2.5**
	1.7, other	2	**3.0**	3	**4.2**	1	**1.3**	1	**1.4**	3	**7.5**
	1.7-1, 1	2	**3.0**	0	**0**	0	**0.0**	2	**2.8**	1	**2.5**
	1.7-1, other	1	**1.5**	1	**1.4**	0	**0.0**	1	**1.4**	0	**0.0**
	1.7-2,4	8	**11.9**	5	**7.0**	3	**4.1**	8	**11.1**	4	**10.0**
	1.7-2, other	4	**6.0**	2	**2.9**	6	**8.2**	11	**15.2**	5	**12.5**
	1.12-1,13	0	**0**	0	**0.0**	0	**0.0**	0	**0.0**	0	**0.0**
	1.12-1, other	2	**3.0**	1	**1.4**	0	**0.0**	0	**0.0**	1	**2.5**
	1.18-1,3	2	**3.0**	0	**0.0**	1	**1.3**	0	**0.0**	0	**0.0**
	1.18-1, other	4	**6.0**	4	**5.6**	5	**6.8**	7	**9.7**	2	**5.0**
	1.19,15-1	1	**1.5**	1	**1.4**	1	**1.3**	1	**1.4**	1	**2.5**
	1.19, other	3	**4.4**	4	**5.6**	5	**6.8**	1	**1.4**	3	**7.5**
	1.22,14	11	**16.4**	21	**29.6**	20	**27.0**	19	**26.3**	2	**5.0**
	1.22,other	4	**6.0**	4	**5.6**	8	**10.8**	4	**5.6**	7	**17.5**
	Other, 1	0	**0.0**	0	**0.0**	0	**0.0**	1	**1.4**	1	**2.5**
	Other, 14	2	**3.0**	4	**5.6**	3	**4.1**	2	**2.8**	0	**0.0**
	Other, 16	1	**1.5**	2	**2.9**	2	**2.7**	3	**4.2**	1	**2.5**
	Subtotal vaccine types	56	**83.6**	61	**86.0**	59	**79.7**	63	**87.5**	35	**87.5**
NVT**	Other **Non Vaccine Type**	11	**16.4**	10	**14.0**	15	**20.3**	9	**12.5**	5	**12.5**
	Total	67	**100.0**	71	**100.0**	74	**100.0**	72	**100.0**	40	**100.0**

*based on a nonavalent PorA vaccine. NonaMen; serosubtypes P1.7,16; P1.5-1,2-2; P1.19,15-1; P1.5-2,10; P1.12-1,13; P1.7-2,4; P1.22,14; P1.7-1,1 and P1.18-1,3,6
**Non vaccine type

4.5.2 FetA

In addition to PorA epitope sequencing, meningococcal isolates are also characterized by FetA epitope sequencing. The outer membrane protein FetA is involved in iron uptake by meningococci and is considered as a potential vaccine component. Therefore, the variability of this protein has been investigated intensely. The most variable part of the protein, called VR, has been used to establish a typing scheme. Analogous to PorA typing, the VR part of *fetA* is sequenced and translated to a putative amino acid sequence. So far, approximately 270 VR sequences comprising 6 classes are identified, which are available at https://pubmlst.org/neisseria/FetA/. (PubMLST)[5] As an example of a type designation: F5-2, in which the first digit indicates the class and the second digit the variant within this class.

In 2020, 15 different FetA variants were observed among serogroup B meningococci, among wich F3-3 (18%), F1-5 (13%) and F5-12 (10%) were the three dominant types (figure 4.7; table 4.9). In previous years, F1-5 constituted the dominant type within serogroup B meningococci (table 4.7), with strong linkage to PorA VR1/VR2 P1.7-2,4. Together, these types linked to the MLST clonal complex ST41/44. In 2020, 5 isolates were of the Fet A type F1-5, of which two were linked to P1.7-2,4 and 3 were linked to different PorA types. In total, 25 different PorA VR1/VR2 combinations and 15 different FetA variants were encountered among serogroup B meningococci. Although the numbers in 2020 are small, frequently found combinations were P1.22,14:F5-5, P1.7-2,4:F1-5, P1.7-2,16:F3-3, P1.22,9:F5-12 and P1.22,9-5:F5-12 (5% each) (Figure 4.7).

In 2020, we received 12 serogroup W samples: 10 isolates and 2 PCR-positive samples. From one PCR samples complete typing was not possible. The 12 meningococcal serogroup W isolates only displayed a single FetA type F1-1 (Figure 4.7, Table 4.9) linked to PorA VR1/VR2 P1.5,2 and MLST clonal complex 11.



	F1-1	F1-5	F1-7	F3-3	F3-4	F4-1	F5-1	F5-2	F5-5	F5-12	Other
B		5	1	7		1	2	2	3	4	14
Y					1	6				2	
W	11										1
E			1								
X	1										1
NG						1			1		

[5] *PubMLST - FetA variable region typing*. Public databases for molecular typing: https://pubmlst.org/neisseria/FetA/

Figure 4.7 *Distribution of meningococcal* fetA *genosubtypes, 2020*

Table 4.9 Temporal distribution in *fetA* genosubtype among *N. meningitidis* serogroups B, C and W isolates, 2016-2020

	Men B					Men C					Men W				
Years / FetA	2016	2017	2018	2019	2020	2016	2017	2018	2019	2020	2016	2017	2018	2019	2020
F1-1	0	0	1	2	0	0	0	0	0	0	43	72	90	53	12
F1-5	16	12	7	12	5	0	1	0	0	0	0	0	1	2	0
F1-7	4	9	4	6	1	0	0	0	1	0	1	0	0	0	0
F3-3	7	7	9	14	7	2	3	1	2	0	0	0	1	0	0
F3-4	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0
F3-6	0	0	1	0	0	2	2	1	1	0	0	0	0	0	0
F3-7	1	0	0	0	0	0	0	0	0	0	0	2	3	1	0
F3-9	2	0	2	1	1	2	2	1	1	0	1	0	0	0	0
F4-1	0	3	2	0	1	0	0	0	0	0	0	1	0	1	0
F5-1	12	17	12	12	2	0	0	0	0	0	0	0	0	0	0
F5-2	1	1	2	3	2	0	0	0	0	0	0	0	0	1	0
F5-5	10	8	11	6	3	0	0	0	0	0	0	0	1	0	0
F5-8	1	0	1	1	3	0	0	0	0	0	0	0	1	0	0
F5-12	3	1	1	3	4	0	0	0	0	0	0	0	0	0	0
F5-36	0	2	1	1	3	0	0	0	0	0	0	0	2	0	0
Other	10	22	20	11	8	0	1	0	1	0	0	6	2	1	0
Total	**67**	**82**	**74**	**72**	**40**	**6**	**9**	**3**	**6**	**0**	**46**	**81**	**102**	**60**	**12**

4.6 Vaccination prospects N. meningitidis

In the Netherlands, vaccination against serogroup C meningococcal disease was introduced in June 2002. All children born on or after June 1st, 2001 are vaccinated at the age of 14 months as part of the regular National Immunisation Programme. In addition, between June 2002 and October 2002, children and adolescents from 12 months to 19 years were vaccinated. In recent years, the number of cases of meningococcal W disease has been increasing in the Netherlands. In response, the MenC vaccine has been replaced by one that protects against meningococcal types A, C, W and Y as of 1 May 2018. Because meningococcal type W is also hazardous for older children and because carriage is highest in this age group, the vaccination is also be offered to teenagers in the year they turn 14, as of 1 October 2018, including a catch-up campaign for 14-18 year olds between October 2018-June 2019. In 2020, no cases due to serogroup C meningococci and only 3 cases of meningococcal W disease were reported in patients < 25 years of age (Figure 4.8).



Years	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Men C	55	78	220	172	24	5	0	0	5	3	2	4	1	1	1	1	3	1	2	0	1	0
Men W	5	11	7	3	4	0	2	0	3	2	2	3	1	1	2	0	2	13	28	28	15	3

Figure 4.8 *Number of N.meningitidis serogroup C and W isolates in patients < 25 years of age, 1999-2020. Start of vaccination with MenC and MenACWY vaccine is indicated in orange and green color, respectively.*

Two meningococcal group B vaccines are registered in the Netherlands but not included in the National Immunization programme (RIVM, meningococcal B vaccination)[6]

[6] RIVM. *Meningokokken B vaccinatie*. (Dutch) https://lci.rivm.nl/richtlijnen/meningokokken-b-vaccinatie

5 HAEMOPHILUS INFLUENZAE

5.1 General features

In total, 202 *Haemophilus influenzae* isolates were submitted to the NRLBM in 2020, which is a decrease compared to the 226 isolates received in 2019 (table 2.3, figure 3.3, figure 5.1). Twenty-one isolates were from CSF (or CSF and blood; 10.3%) and 181 from blood only (89.7%). Sixty-five (32%) of the isolates were *H. influenzae* type b (table 5.1), which is the highest number since the introduction of vaccination in 1993 (figure 5.3). The increase is visible among different age groups (Figure 5.5).



Figure 5.1 *Number of received H. influenzae isolates according to source of isolation, 2011-2020*

5.2 Antibiotic susceptibility

The proportion of ß-lactamase-producing invasive *H. influenzae* isolates (CSF and/or blood) was 8.4% in 2020 (Figure 5.2). During the history of the NRLBM, the proportion of ß-lactamase-producing invasive *H. influenzae* isolates has always fluctuated for unknown reasons.



Figure 5.2 *Percentage β-lactamase-producing H. influenzae strains among received isolates, 2011-2020*

5.3 Serotype and age

In 2020, the number of *H. influenzae* type b isolates increased compared to the previous year, representing almost one-third of all received *H. influenzae* isolates compared to approximately 16% in 2019. This is the the highest number of *H. influenzae* b isolates in the last 15 years (Figure 5.3). Currently, it is unclear what causes this increase in *H. influenzae* b, especially when most other respiratory-transmitted pathogens decreased as a result of Covid-19 containment measures. We observed 20 cases of invasive *H. influenzae* type b disease among children younger than 2 years of age (Table 5.1 and figure 5.4; 11 in 2019; 15 in 2018; 7 in 2017). In contrast, the number of non-typeable *H. influenzae* isolates decreased for the first time in 20 years, representing 58% of all received isolates (118 of 202 isolates), compared to 73% of all isolates in 2019 (Figure 5.3). Five non-typeable isolates were isolated from CSF (or CSF and blood) and 113 were isolated from blood only (table 5.1). Since 2000, the number of non-typeable *H. influenzae* isolates has steadily increased, which also explains the rise in total *H. influenzae* invasive infections over the same period (Figure 5.3). In addition, since 2008, the number of cases due to serotype f has been slowly increasing, but are still below the numbers of *H. influenzae* b (Figure 5.3).

Table 5.1 Serotype distribution of all received *H. influenzae isolates* according to serotype patient's age, 2020

	AGE (MONTHS)				AGE (YEARS)					TOTAL	
Type	**0**	**1-11**	**12-23**	**24-59**	**0-4**	**5-9**	**10-19**	**20-49**	**≥50**	**T**	**%**
Hi - a	0	2	0	0	2	0	0	0	2	**4**	***2.0***
CSF	*0*	*1*	*0*	*0*	*1*	*0*	*0*	*0*	*0*	***1***	
Blood	*0*	*1*	*0*	*0*	*1*	*0*	*0*	*0*	*2*	***3***	
Hi - b	1	10	9	7	27	4	0	10	25	**66**	***32.7***
CSF	*0*	*6*	*0*	*3*	*9*	*0*	*0*	*1*	*1*	***11***	
Blood	*1*	*4*	*9*	*4*	*18*	*4*	*0*	*9*	*24*	***55***	
Hi - e	0	1	0	1	2	0	0	0	3	**5**	***2.5***
CSF	*0*	*1*	*0*	*1*	*2*	*0*	*0*	*0*	*0*	***2***	
Blood	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*3*	***3***	
Hi - f	0	0	0	1	1	0	0	0	8	**9**	**4.4**
CSF	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*2*	***2***	
Blood	*0*	*0*	*0*	*1*	*1*	*0*	*0*	*0*	*6*	***7***	
n.t.*	4	0	4	1	9	2	4	14	89	**118**	***58.4***
CSF	*0*	*0*	*2*	*0*	*2*	*0*	*1*	*0*	*2*	***5***	
Blood	*4*	*0*	*2*	*1*	*7*	*2*	*3*	*14*	*87*	***113***	
Total	**5**	**13**	**13**	**10**	**41**	**6**	**4**	**24**	**127**	**202**	***100.0***
CSF	***0***	***8***	***2***	***4***	***14***	***0***	***1***	***1***	***5***	***21***	***10.4***
Blood	***5***	***5***	***11***	***6***	***27***	***6***	***3***	***23***	***122***	***181***	***89.6***
%	***1.3***	***6.2***	***2.7***	***4.0***	***20.3***	***3.0***	***2.0***	***11.9***	***62.8***	***100.0***	

* non-typeable



Figure 5.3 *Number of cases due to H. influenzae serotypes b,f and non-typeable H. influenzae, 1992-2020*



Figure 5.4 *Age distribution among children < 2 years of age of H. influenzae type b invasive disease for indicated years between 1992 - 2020. The H. influenzae type b vaccine was introduced in 1993.*



Figure 5.5 D*istribution of H. influenzae type b (CSF and/or blood) per age group. 2016-2020.*

5.4 Distribution of non-typeable H. influenzae

The proportion of non-typeable *H. influenzae* isolates increased from 6% in 1992 to about 73% in 2019 and decreased to 58% in 2020 (table 5.2), likely as a result of Covid-19 containment measures. The vast majority of non-typeable *H. influenzae* isolates are from blood (95%) in accordance to previous years (Table 5.2 and figure 5.6). Most cases of bacteremia caused by non-typeable *H. influenzae* occur in adults above the age of 50 (Tables 5.1 and 5.2). Among non-typeable *H. influenzae* isolates, biotype II was the predominant biotype during the last ten years (Figure 5.7).

Table 5.2 Number and proportion of non-typeable *H.influenzae isolates* from CSF and/or blood according to age, 2011- 2020

n.t.*	0-4	5-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	≥80	T	Csf / Blood	% **
2011	10	3	4	5	3	5	9	14	20	14	**98**	6/92	70.5
2012	16	0	2	1	13	6	10	18	21	14	**101**	12/89	72.1
2013	8	1	2	1	7	4	5	27	29	31	**115**	6/109	71.9
2014	11	2	0	5	6	5	11	31	27	19	**117**	15/102	72.7
2015	12	3	1	5	6	9	19	34	19	24	**132**	14/118	67.7
2016	10	1	0	3	6	6	9	39	25	24	**123**	10/113	65.4
2017	18	1	3	4	8	11	16	33	37	28	**159**	21/138	71.0
2018	16	2	7	5	8	9	14	30	32	45	**168**	9/159	70.3
2019	12	0	2	8	14	8	17	29	39	35	**164**	12/152	72.6
2020	9	2	4	5	2	7	13	24	30	21	**118**	5/113	58.4

* non-typeable

** % non-typeable / total *H. influenza* isolates



Figure 5.6 *Non-typeable H. influenzae isolates from CSF or blood received between 1992 - 2020*



Figure 5.7 *Biotype distributions of non-typeable H. influenzae isolates from CSF and/or blood from 2011 – 2020.*

5.5 Geographical distribution of H. influenza

We also plotted the geographical distribution of all *H. influenzae* cases (Fig. 5.8A) and *H. influenzae* b cases (Fig. 5.8B) per 100,000 inhabitants based on the patient's residence to identify whether there was indication for clustering. No apparent pattern emerged from this visualization.

Figure 5.8. Geographical visualization of H. influenzae incidence for (A) all *H. influenzae* types and (B) *H. influenzae* b cases. Incidence is calculated per 100,000 inhabitants and place of residence of patient.



5.6 Vaccination prospects H. influenzae

The first implemented *H. influenzae* b vaccine consisted of the type b capsular polysaccharide conjugated to the tetanus toxoid protein (PRP-T). Since July 1993, children born after the 1st of April 1993 were vaccinated with the PRP-T vaccine, at the ages of 3, 4, 5, and 11 months. In 1999, the vaccine was administrated at the age of 2, 3, 4 and 11 months. In 2002, the Hib vaccine was given in combination with a pentavalent combination vaccine together with DTwP-IPV/Hib, with the whole cell pertussis (wP) component being changed to the acellular pertussis vaccine in 2004 (DTaP-IPC/Hib). In 2011, the Hepatitis B vaccine was added to this pentavalent combination vaccine (Infantrix^{TM} hexa). From Dec 2018, the composition of the administrated Hib conjugate vaccine in this hexavalent combination vaccine was changed from tetanus toxoid to a *N. meningitidis* outer membrane protein complex (OMPC). Finally, the vaccination schedule for this hexavalent vaccine that includes the Hib component has changed from a 3+1 to a 2+1 schedule (administrated at 3, 5, and 11 months of age) from January 2020.

The effect of vaccination on the frequency of *H. influenzae* meningitis cases is shown in figure 5.9 The number of *H. influenzae* meningitis cases caused by *H. influenzae* type b showed a steep decline since the introduction of the vaccine, while the number of meningitis cases caused by *H. influenzae* non-type b remained similar. In 2020, we received 32 *H. influenzae* type b isolates (31 isolates and one CSF PCR positive sample) from patients that were vaccine-eligible (<27 years of age); 9 patients (8 CSF culture positive, 1 CSF PCR positive) and 23 from blood. (CSF cases 2019: 7; 2018: 9; 2017: 7) (figures 5.9 and 5.10). Of the 9 meningitis patients, eight patients were not (completely) vaccinated at all and from one patient, vaccination status was unknown.



Figure 5.9 *The number of H. influenzae type b and non-type b meningitis cases, 1990 - 2020*

Figure 5.10 *The number of H. influenzae type b cases (CSF or blood) among patients eligible for vaccination and among older patients, 2000 –2020*

6 STREPTOCOCCUS PNEUMONIAE

6.1 General features

From 2003 onwards, the NRLBM requested nine sentinel laboratories, evenly distributed across the country and covering 25% of the Dutch population, to submit pneumococcal isolates from CSF and/or blood from patients of all ages. All medical microbiology laboratories were requested to submit pneumococcal isolates from CSF (or CSF and blood), representing meningitis patients. From 2006, the 7-valent pneumococcal polysaccharide conjugate vaccine (PCV7) was introduced in the National Immunisation Programme and all medical microbiology laboratories were requested to submit all invasive pneumococcal isolates from patients in the age group 0-4 years. PVC7 was replaced by the 10-valent pneumococcal polysaccharide conjugate vaccine (PCV10) from March 1, 2011 onwards. Criteria for isolate submission remained similar until 2017, when all medical microbiology laboratories were requested to submit all invasive pneumococcal isolates without restriction to age of the patient. In 2020, the NRLBM received 1,115 isolates nationwide of which 382 (34%) pneumococcal isolates (CSF and/or blood) were received from the 9 sentinel laboratories. Of the 1,115 nationwide submitted isolates, 105 isolates were from CSF (or CSF and blood). The NRLBM also received 7 PCR-positive, culture-negative (CSF or blood) samples. The incidence of pneumococcal meningitis gradually increased from 1.0 per 100,000 individuals in 1990 to 1.6 per 100,000 individuals in 2004. The introduction of the PCV7/PCV10 vaccin decreased pneumococcal meningitis incidence to 0.6 per 100,000 individuals in 2020 (Figure 6.1).



Figure 6.1 *Number of submitted S. pneumoniae isolates and invasive pneumococcal disease incidence based in isolates from blood or CSF, 2000-2020*

Figure 6.2 shows the number of *S. pneumoniae* isolates and incidence according to the patients' age. The incidence of pneumococcal meningitis is highest among patients in the age groups 0-4 and 60-74 years (Figure 6.2; top graph), whereas incidence of pneumococcal bacteremia is highest in patients 75-94 (Figure 6.2,; bottom graph). The absolute number of isolates from patients with bacteremia is highest in the age group 60-74 years (Figure 6.2; bottom graph). Figure 6.3 shows the geographical distribution of invasive pneumococcal disease per township based on patient's place of residence and per 100,000 inhabitants.



Figure 6.2 *S. pneumoniae isolates received per age group and incidence per 100,000 inhabitants according to isolation source in 2020. Top graph: isolates from CSF/CSF and blood. Bottom graph: isolates from blood only (9 sentinel labs)*

S. pneumonia meningitis

S. pneumonia bacteremia



Figure 6.3 *Geographical distribution of S. pneumoniae invasive disease incidence per 100,000 inhabitants, left; meningitis based on isolates from CSF or CSF and blood, right; bacteremia based on isolates from blood only (nationwide). Data plotted based on patient's place of residence.*

6.2 Antibiotic susceptibility

Among 345 isolates from blood only (9 sentinel labs), 15 (4%) isolates were intermediately susceptible to penicillin (0.06 < MIC ≤ 2.0 mg/L; table 6.1). Among the blood isolates received from labs nationwide, one isolate (0.1%) was resistant to penicillin (Table 6.1). Among 108 nationwide patients with *S. pneumoniae* from CSF (or CSF and blood), 10 (9.3%) strains were resistant to penicillin (MIC > 0.06 mg/L). From 3 patients no MIC values were obtained as no *S. pneumoniae* isolate was available.

Table 6.1 Penicillin susceptibility of *S. pneumoniae* isolates, 2020

	Penicillin*				
MIC for CSF isolates (Nationwide)	**S MIC ≤ 0.06**	**I**	**R MIC > 0.06**	**ND** (PCR)**	**Total**
CSF/CSF and blood	95	n.a.	10	(3)	108
MIC for blood isolates	**MIC ≤ 0.06**	**0.06< MIC ≤ 2.0**	**MIC >2.0**		
Blood only (9 sentinel labs)	330	15	0	(0)	345
Blood only (nationwide)	958	48	1	(0)	1007

* MIC values in mg/L according to EUCAST guidelines
** No MIC value known because no isolate was available (PCR-positive patient)
n.a. not applicable for meningitis

6.3 Distribution according to serotype

The distribution of serotypes, grouped by vaccine type (VT) and by age of the patient, for isolates from CSF (or CSF and blood) or blood only (submitted by the 9 sentinel labs) is presented in tables 6.2 and 6.4, respectively. Disease caused by PCV10-covered serotypes is less than 3% for meningitis (table 6.2) and less than 5% for bacteremia (table 6.4). Serotypes that would be additionally covered by the PCV13 vaccine (serotypes 3, 6A and 19A) account for approximately 32% and 25% of all isolates from meningitis and bacteremia patients, respectively (Tables 6.2, 6.4). The incidence of pneumococcal meningitis per 100,000 inhabitants per vaccine type and age of the patient is shown in table 6.3. Incidence of meningitis caused by PCV10 vaccine types is nearly eliminated in all age groups. Nonetheless, meningitis incidence is still highest in the age group 0-11 months, followed by non-vaccinated age groups 50-64 and 65-79 as a result of disease caused by non-PCV10 serotypes (Table 6.3). As aforementioned in 6.1, incidences of *S. pneumoniae* from blood only are incomplete. Effect of PCV10 introduction on serotype distribution among meningitis and bacteremia patients can be seen in tables 6.5 and 6.6, respectively. There is an overall reduction in the number of PCV10-covered serotypes for the period 2010-2020 of >90%. However, the overall number of invasive pneumococcal disease isolates has remained fairly consistent up to 2019 due to an increase in the number of isolates of non-vaccine serotypes. Especially serotypes 3, 8 and 19A have been showing in increase over these years. Serotypes 3 and 19A would be covered by PCV13 and serotype 8 by PPV23. In 2020 though, a decrease of ~40% in the total number of submitted pneumococcal isolates from invasive disease was observed, which is likely the result of the COVID-19 containment measures that also impact pneumococcal transmission.

Table 6.2 Serotype and age distribution of *S. pneumoniae* isolates from CSF (or CSF and blood; nationwide isolation collection), 2020. Serotypes are grouped by vaccine type.

			AGE (MONTHS)			AGE (YEARS)											
		TYPE	0	1-11	12-59	0-4	5-9	10-14	15-19	20-29	30-39	40-49	50-64	65-79	≥80	Total	%
23-valent vaccine (all above types except 6A)	13-valent vaccine	10-valent vaccine 1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		6B	-	-	-	-	-	-	-	-	-	-	1	1	-	2	
		7F	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		9V	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		14	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		18C	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		19F	-	-	-	-	-	-	-	-	-	-	-	1	-	1	
		23F	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		Subtotal PCV10	-	-	-	-	-	-	-	-	-	-	*1*	*2*	-	*3*	***2.8***
		3	-	-	-	-	-	-	-	-	3	5	6	6	-	20	
		6A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		19A	-	3	2	5	-	1	-	-	-	3	3	3	-	15	
		Subtotal PCV13	-	*3*	*2*	*5*	-	*1*	-	-	*3*	*8*	*10*	*11*	-	*38*	***35.2***
		2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		8	-	1	-	1	-	-	-	-	-	1	3	3	-	8	
		9N	-	-	-	-	-	-	-	-	-	-	3	1	-	4	
		10A	-	1	1	2	-	-	-	-	-	-	-	-	-	2	
		11A	-	-	-	-	-	-	-	-	-	1	1	2	-	4	
		12F	-	-	-	-	-	-	-	-	-	2	-	1	-	3	
		15B	-	-	-	-	-	-	-	-	-	-	-	1	-	1	
		17F	-	-	-	-	-	-	-	-	-	-	-	-	1	1	
		20	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		22F	-	-	-	-	-	-	-	-	1	-	4	1	-	6	
		33F	-	-	-	-	-	-	-	-	-	-	-	1	-	1	
Subtotal PPV23			-	*5*	*3*	*8*	-	*1*	-	-	*4*	*12*	*21*	*21*	*1*	*68*	***63.0***
		Other	-	1	-	1	3	-	-	-	3	3	10	16	1	37	***34.2***
		Type unknown	-	-	-	-	-	-	-	-	1	1	1	-	-	3	***2.8***
		Total	**-**	**6**	**3**	**9**	**3**	**1**	**-**	**-**	**8**	**16**	**32**	**37**	**2**	**108**	***100.0***

*Total 23 valent vaccine= sum of all above types – 6A
* From 3 patients with a pneumococcus detected in CSF there is no serotype known

Table 6.3 Age-specific incidence of pneumococcal meningitis nationwide (isolates from CSF or CSF and blood) per 100,000 inhabitants according to vaccine serotype, 2020

	AGE (YEARS)											
TYPE	0	1-4	5-9	10-14	15-19	20-29	30-39	40-49	50-64	65-79	≥80	Total
10-valent	-	-	-	-	-	-	-	-	0.03	0.08	-	0.02
13-valent	1.77	0.29	-	0.10	-	-	0.14	0.36	0.27	0.43	-	0.22
23-valent	2.95	0.43	-	0.10	-	-	0.19	0.54	0.58	0.82	0.12	0.39
Other	0.59	-	0.33	-	-	-	0.19	0.18	0.30	0.62	0.12	0.23
Total	**3.54**	**0.43**	**0.33**	**0.10**	**-**	**-**	**0.37**	**0.72**	**0.88**	**1.44**	**0.24**	**0.62**

Table 6.4 Serotype and age-dependent distribution of *S. pneumoniae* isolates from blood submitted by the 9 sentinel laboratories, 2020.

			AGE (MONTHS)			AGE (YEARS)											
		TYPE	0	1-11	12-59	0-4	5-9	10-14	15-19	20-29	30-39	40-49	50-64	65-79	≥80	Total	%
23-valent vaccine (all above types except 6A)	13-valent vaccine	10-valent vaccine 1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		4	-	-	-	-	-	-	-	-	-	2	2	1	1	6	
		5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		6B	-	-	-	-	-	-	-	-	-	-	-	1	-	1	
		7F	-	-	-	-	-	-	-	-	-	-	-	-	1	1	
		9V	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		14	-	-	-	-	-	-	-	-	1	-	2	1	4	8	
		18C	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		19F	-	-	-	-	-	-	-	-	-	1	-	-	-	1	
		23F	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		Subtotal PCV10	-	-	-	-	-	-	-	-	*1*	*3*	*4*	*3*	*6*	*17*	***4.9***
		3	-	-	1	1	-	-	-	-	2	3	8	13	3	30	
		6A	-	-	-	-	-	-	-	-	-	-	-	-	1	1	
		19A	-	1	2	3	1	-	-	2	2	-	15	17	14	54	
		Subtotal PCV13	-	*1*	*3*	*4*	*1*	-	-	*2*	*5*	*6*	*27*	*33*	*24*	*102*	***29.6***
		2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		8	-	1	-	1	-	-	1	2	5	7	23	39	11	89	
		9N	-	-	-	-	-	-	-	-	-	2	5	8	5	20	
		10A	-	-	-	-	-	-	-	-	2	-	2	6	3	13	
		11A	-	-	-	-	1	-	-	-	-	-	-	5	1	7	
		12F	-	1	-	1	-	-	-	-	1	-	2	5	3	12	
		15B	-	-	-	-	-	-	-	-	-	-	1	1	1	3	
		17F	-	-	-	-	-	-	-	-	-	-	1	1	2	4	
		20	-	-	-	-	-	-	-	-	-	1	1	-	1	3	
		22F	-	-	-	-	-	-	-	-	1	1	5	10	7	24	
		33F	-	-	-	-	-	-	-	-	-	-	-	5	1	6	
Subtotal PPV23			-	*3*	*3*	*6*	*2*	-	*1*	*4*	*14*	*17*	*67*	*113*	*58**	*282*	***81.7***
		Other	-	-	3	3	1	-	-	-	-	4	14	26	14	62	***18.0***
		Total	**-**	**3**	**6**	**9**	**3**	**-**	**1**	**4**	**14**	**21**	**81**	**139**	**73**	**345**	***100.0***

*Total 23 valent vaccine= sum of all above types – 6A

Table 6.5 Changes in serotype distribution of pneumococcal CSF isolates (nationwide isolate collection). Introduction of PCV10 in Immunisation Programme is shaded in gray, 2010-2020

			TYPE	2010	2011*	2012	2013	2014	2015	2016	2017	2018	2019	2020
23-valent vaccine (all above types except 6A)	13-valent vaccine	10-valent vaccine	1	3	1	1	3	4	1	2	1	-	-	-
			4	3	2	4	2	2	-	1	1	2	1	-
			5	2	-	3	-	-	-	-	-	-	-	-
			6B	-	2	-	-	-	1	-	-	-	-	2
			7F	20	28	16	15	8	7	4	2	2	1	-
			9V	2	-	3	1	1	-	2	-	-	-	-
			14	5	2	1	-	-	1	-	-	2	-	-
			18C	5	5	2	2	-	1	-	1	1	1	-
			19F	2	6	4	2	4	2	5	6	1	3	1
			23F	4	2	1	-	-	1	-	1	-	-	-
			Subtotal PCV10	*46*	*48*	*35*	*25*	*19*	*14*	*14*	*12*	*8*	*6*	*3*
			3	20	7	13	16	13	16	25	20	20	21	20
			6A (not in 23 valent)	5	1	1	1	3	-	1	-	-	-	-
			19A	20	16	6	9	7	10	8	16	13	20	15
			Subtotal PCV13	*91*	*72*	*55*	*51*	*42*	*40*	*48*	*48*	*41*	*47*	*38*
			2	-	-	-	-	-	-	-	-	-	-	-
			8	10	17	9	16	23	24	18	21	23	26	8
			9N	6	7	4	2	6	6	3	6	4	4	4
			10A	9	7	9	7	12	5	7	7	7	11	2
			11A	1	5	1	1	3	2	3	2	8	-	4
			12F	3	7	10	9	8	9	12	8	11	5	3
			15B	2	3	1	-	-	-	5	7	2	7	1
			17F	4	3	1	1	1	-	-	1	2	-	1
			20	1	-	-	1	1	1	-	-	-	-	-
			22F	14	16	11	8	8	11	11	8	8	10	6
			33F	7	5	6	3	2	4	4	6	6	3	1
			Subtotal PPV23*	*143*	*141*	*106*	*98*	*103*	*102*	*110*	*114*	*112*	*113*	*68*
			6C	3	4	2	6	3	6	5	3	3	11	12
			7B	-	-	-	1	-	-	-	-	-	-	2
			7C	-	-	-	-	-	-	-	-	-	1	-
			10F	-	-	-	-	-	-	-	-	-	-	-
			10B	-	-	1	-	1	1	-	1	-	1	1
			12A	-	-	-	-	-	-	-	-	-	-	-
			13	-	-	-	-	-	-	-	-	-	-	-
			15A	1	1	1	4	6	7	2	4	3	1	-
			15C	2	-	3	-	-	1	-	3	1	1	1
			16F	5	4	-	5	2	1	3	1	5	-	-
			17A	-	-	-	-	-	-	-	-	-	-	-
			18F	-	-	-	-	-	-	-	-	-	-	-
			18A	-	-	-	-	-	-	-	-	-	-	-
			18B	-	-	1	-	-	-	-	-	-	-	-
			21	-	1	-	-	-	-	-	-	2	-	1
			22A	1	-	-	-	-	1	1	-	-	-	-
			23A	3	2	4	4	4	5	5	5	8	6	5
			23B	5	2	5	7	8	11	6	11	8	10	9
			24F	1	1	4	4	7	7	1	2	1	5	-
			24B	-	-	2	-	-	-	-	-	-	-	-
			25	-	-	-	-	-	-	-	-	-	-	-
			27	-	-	1	-	2	1	1	-	1	1	1
			28F	-	-	-	1	-	-	-	-	-	-	-
			28A	-	1	-	-	-	-	-	-	-	-	-
			29	-	-	1	-	-	-	-	-	-	-	-
			31	1	-	1	-	1	-	1	1	-	-	-
			33A	-	-	-	-	-	-	-	-	-	-	-
			34	-	1	-	-	-	1	1	1	2	2	1
			35F	4	1	-	2	1	2	5	1	3	3	4
			35B	1	-	1	3	1	1	1	-	2	-	-
			35D	-	-	-	-	-	-	-	-	1	1	-
			37	-	1	2	1	-	-	-	-	-	-	-
			38	1	-	2	1	-	-	-	-	-	2	-
			Rough (n.t.)	-	-	-	-	-	-	-	1	-	-	-
			Type unknown	-	-	-	-	-	-	-	-	-	10	3
			Total	176	163	138	138	142	147	143	148	152	165	108

Table 6.6 Changes in serotype distribution of *S. pneumoniae* from blood submitted by the 9 sentinel laboratories, 2010-2020. Serotypes are grouped by vaccine type.

		TYPE	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
23-valent vaccine (all above types except 6A)	13-valent vaccine	10-valent vaccine	1	53	40	50	40	41	41	22	8	8	-	-
			4	17	27	11	13	6	6	6	6	6	1	6
			5	7	11	8	9	2	1	-	1	-	-	-
			6B	8	3	3	3	3	4	1	-	2	3	1
			7F	72	91	92	75	53	56	36	27	23	4	1
			9V	21	5	2	4	1	5	-	2	3	-	-
			14	22	19	12	8	2	7	8	4	2	7	8
			18C	7	8	4	8	2	2	2	1	1	-	-
			19F	5	9	3	5	7	8	6	9	7	4	1
			23F	13	5	3	1	2	1	1	1	-	1	-
			Subtotal PCV10	*225*	*218*	*188*	*166*	*119*	*131*	*82*	*59*	*52*	*20*	*17*
			3	30	36	45	40	31	35	45	51	71	45	30
			6A (not in 23 valent)	9	2	6	2	-	2	-	4	4	1	1
			19A	57	63	78	61	44	78	75	82	101	84	54
			Subtotal PCV13	*321*	*319*	*317*	*269*	*194*	*246*	*202*	*196*	*228*	*150*	*102*
			2	-	-	-	-	-	-	-	-	-	-	-
			8	60	59	88	108	93	136	151	143	159	146	89
			9N	19	17	20	19	21	26	32	29	31	31	20
			10A	9	14	8	6	16	15	11	11	8	10	13
			11A	12	9	14	16	8	6	6	9	8	5	7
			12F	13	19	25	22	28	30	18	28	22	26	12
			15B	7	4	1	7	7	2	8	6	8	10	3
			17F	4	8	7	4	8	6	6	5	4	2	4
			20	3	4	-	1	4	2	3	5	6	10	3
			22F	29	37	41	45	34	43	28	39	45	47	24
			33F	10	15	22	12	12	19	18	12	28	13	6
			Subtotal PPV23*	*478*	*503*	*537*	*507*	*425*	529	483	*479*	*543*	449	282
			6C	9	7	10	10	7	21	20	15	24	22	18
			7B	-	-	-	-	-	-	-	-	1	1	3
			7C	-	-	-	-	-	-	-	-	1	4	5
			9A	-	-	1	-	1	-	1	-	-	-	-
			10F	-	-	-	-	1	-	-	-	-	-	-
			10B	-	-	-	1	-	-	-	1	2	2	1
			11B	-	-	-	-	-	-	-	-	-	2	-
			11D	-	-	-	-	-	-	-	-	-	3	2
			12A	-	-	-	-	-	-	-	-	1	-	-
			13	-	1	-	-	-	-	1	-	-	-	-
			15F	-	-	-	1	-	-	1	-	-	-	-
			15A	-	2	7	13	14	18	21	16	14	12	7
			15C	1	2	1	4	4	3	2	1	1	3	1
			16F	10	7	6	7	5	2	9	9	5	4	5
			17A	-	2	-	-	-	-	-	-	-	-	-
			18F	-	-	-	-	-	2	-	-	-	-	-
			18A	1	1	-	-	-	-	-	-	-	-	-
			18B	-	-	1	1	-	-	-	-	-	-	-
			21	-	-	-	2	1	-	-	1	1	-	2
			22A	1	1	-	1	-	1	-	-	1	-	-
			23A	7	2	6	6	7	7	12	15	14	11	6
			23B	3	9	3	6	15	5	11	17	11	17	4
			24F	2	3	2	4	4	7	1	6	3	7	-
			25F	-	-	-	-	-	1	-	1	-	-	-
			27	-	1	-	1	-	1	1	-	-	-	-
			28	-	-	-	-	-	-	-	-	-	1	-
			29	-	-	1	-	-	-	-	-	-	-	-
			31	4	2	6	2	2	4	4	3	6	1	-
			33A	-	-	1	-	-	-	1	-	1	-	-
			34	1	-	1	2	1	-	1	1	3	4	1
			35F	5	6	5	6	7	7	6	3	6	3	3
			35A	-	-	1	-	-	-	-	-	-	-	-
			35B	-	3	1	7	6	8	8	2	8	3	3
			35D	-	-	-	-	-	-	-	-	-	2	-
			37	1	-	-	-	1	1	-	-	-	-	-
			38	-	3	-	1	2	2	1	5	4	1	1
			40	-	-	-	1	-	-	-	-	-	-	-
			Rough (n.t.)	-	2	-	-	-	-	-	1	1	1	-
			Total	532	559	596	585	503	621	584	580	655	556	345

6.4 Vaccination

The first pneumococcal polysaccharide conjugated vaccine contained 7 serotype-specific polysaccharides linked to inactive diphtheria toxin (PCV7). Since July 2006, children born after the 1st April 2006 are vaccinated with PCV7 at the ages of 2, 3, 4 and 11 months. In April 2011, the 10-valent vaccine (PCV10) was introduced for all newborns from March 1st 2011. In 2020, 2.8% of the CSF isolates were of a serotype covered by the PCV10 vaccine (table 6.2). There were only 3 patients with pneumococcal meningitis due to pneumococci with a PCV-10 vaccine serotype (6B and 19F; Table 6.5). All three patients were not vaccinated because of age (57, 67 and 70 years of age). The beneficial effect of vaccination is partly countered by an increase in the number of cases due to non-vaccine types (figure 6.4).

The pneumococcal polysaccharide vaccine covers 23 serotypes (PPV23). Sixty-three percent of the CSF isolates were of a serotype that would be covered by this vaccine (table 6.5). (2020: 63%; 2005: 90% pre-vaccination). In 2020, 73-79 year-olds are offered a vaccination with PPV23 through the National Immunisation Programme.



Figure 6.4 *The age distribution of S.pneumoniae invasive disease due to pneumococci of serotypes included in PCV-10, 2004-2020. (n PCV-10 type / n total CSF isolates)*

7 ESCHERICHIA COLI

The NRLBM received 94 *Escherichia coli* isolates, 19 isolated from CSF (or CSF and blood) and 75 from blood only (Figure 7.1, Table 7.1). Sixty-three percent of the *E. coli* meningitis cases occurred in the first month of life (Table 7.1). Overall, over 95% of invasive diseases cases caused by *E. coli* are in the age group 0-4 years (Table 7.1), matching with isolate submission criteria. From 2010-2016, the number of received isolates was rather stable with 15-30 isolates per year. From 2017, there is a marked increase, especially in received blood isolates, which is likely explained by increased submission as result of an ongoing study on neonatal meningitis (NOGBS study)[7]



Figure 7.1 *Number of E. coli isolates received according to isolation source, 2011-2020*

Since 2016, K1 expression is determined by phage typing. In 2019, approximately 50% of the received *E. coli* isolates carried the K1 antigen (Table 7.1).

[7] *NOGBS study* Neuroinfecties Amsterdam: https://meningitisamc.nl/professionals/wetenschappelijk-onderzoek-professionals/nogbs-studie

Table 7.1 Number of *E. coli* isolates grouped according to serotype, patient's age, and source of isolation, i.e. CSF and/or blood, 2020

	AGE (MONTHS)			AGE (YEARS)					TOTAL	
Group	**0**	**1-11**	**12-59**	**0-4**	**5-9**	**10-19**	**20-49**	**≥50**	**T**	**%**
Non K1	31	14	1	46	0	0	0	2	**48**	***51***
CSF	*1*	*0*	*0*	*1*	*0*	*0*	*0*	*2*	***3***	
Blood	*30*	*14*	*1*	*45*	*0*	*0*	*0*	*0*	***45***	
K1	35	9	0	44	0	0	0	2	**46**	***49***
CSF	*11*	*3*	*0*	*14*	*0*	*0*	*0*	*2*	***16***	
Blood	*24*	*6*	*0*	*30*	*0*	*0*	*0*	*0*	***30***	
Total	**66**	**23**	**1**	*90*	*0*	*0*	*0*	*4*	**94**	***100***
CSF	*12*	*3*	*0*	*15*	*0*	*0*	*0*	*4*	*19*	*20*
Blood	*54*	*20*	*1*	*75*	*0*	*0*	*0*	*0*	*75*	*80*
%	***70.2***	***24.5***	***1.0***	***95.7***	***0***	***0***	***0***	***4.3***	***100***	

Since 2012, *E. coli* isolates received by the NRLBM are additionally classified by O- and H-typing using Whole Genome Sequencing. O-typing refers to the O-group-specific genes within the O-antigen gene clusters, whereas H-typing determines the H-antigen genes that encode for the different flagellar types. Within the K1 isolates, 52% were of H-type H7 and 17% of type H4. H-type H4 was also dominant among the non-K1 isolates (22%), with H18 and H1 accounting together for one-third of the non-K1 isolates (table 7.2)

Table 7.2 H-type distribution among K1 and non-K1 *E. coli* isolates from CSF or blood, 2016-2020

TYPE	K1 / Non K1	K1 / Non K1	K1 / Non K1	K1 / Non K1	K1 / Non K1
	2016	**2017**	**2018**	**2019**	**2020**
H1	0 / 2	0 / 7	1 / 6	1 / 9	0 / 5
H4	6 / 7	4 / 1	3 / 7	7 / 12	8 / 8
H5	4 / 2	1 / 4	3 / 3	5 / 9	3 / 8
H6	4 / 1	3 / 1	2 / 2	1 / 1	6 / 0
H7	7 / 3	9 / 2	17 / 1	22 / 3	27 / 1
H9	0 / 2	0 / 4	0 / 1	-	0 / 1
H18	0 / 5	0 / 3	0 / 6	3 / 10	0 / 8
H31	-	0 / 2	-	0 / 3	0 / 4
Other	3 / 4	2 / 7	4 / 6	3 / 7	2 / 13
Total	**24 / 26**	**19 / 30**	**30 / 32**	**42 / 54**	**46 / 48**

The types O6 (15%), O25 (10%) and O25 (15%) are most prevalent among non-K1 isolates, while the type O1 (37%) and O50/O2 (20%) are most frequent among K1 isolates. The 11 isolates showed in the group 'Other' were all different O-types (Figure 7.2)



Figure 7.2 Distribution of O-types among K1 and non-K1 *E. coli* isolates from CSF and/or blood, 2020

Among K1 isolates, the O/H combination O1:H7 (37%) was most prevalent while among non-K1 isolates, O25:H4 was dominant (8%)(Figure 7.3).



Figure 7.3 Distribution of O- and H-type combinations among K1 and non-K1 *E. coli* isolates from CSF and/or blood, 2020

*O13 = O13/O135

O50 = O50/O2

8 STREPTOCOCCUS AGALACTIAE – (group B)

In 2020, the NRLBM received 129 *Streptococcus agalactiae* isolates, which is an increase compared to the 120 isolates in 2019 and 106 isolates in 2018 (figure 8.1). Twenty-two (17%) *S. agalactiae* isolates were from CSF (or CSF and blood) and 107 (83%) from blood only (table 8.1, figure 8.1). Seventy-seven percent of all the cases occurred in the first month of life, which was similar for blood and CSF isolates. Overall over 98% of invasive *S. agalactiae* disease cases occurred within the age group 0-4 years (table 6.1). As in previous years, Serotype III was most prevalent (table 8.1, figure 8.2). From 2017, there is a marked increase, especially in received blood isolates, which is likely explained by increased submission as result of an ongoing study on neonatal meningitis (NOGBS study)[8].



Figure 8.1 *Distribution of S. agalactiae isolates, 2011 - 2020*

[8] *NOGBS study* Neuroinfecties Amsterdam: https://meningitisamc.nl/professionals/wetenschappelijk-onderzoek-professionals/nogbs-studie

Table 8.1 Serotypes of *S. agalactiae* isolates from CSF and/or blood, by age of patients, 2020

	AGE (MONTHS)			AGE (YEARS)					TOTAL	
Group	**0**	**1-11**	**12-59**	**0-4**	**5-9**	**10-19**	**20-49**	**≥50**	**T**	**%**
Ia	16	1	0	17	0	0	0	1	**18**	***14.0***
CSF	*1*	*0*	*0*	*1*	*0*	*0*	*0*	*1*	***2***	
Blood	*15*	*1*	*0*	*16*	*0*	*0*	*0*	*0*	***16***	
Ib	4	1	0	5	0	0	0	0	**5**	***3.8***
CSF	*1*	*0*	*0*	*1*	*0*	*0*	*0*	*0*	***1***	
Blood	*3*	*1*	*0*	*4*	*0*	*0*	*0*	*0*	***4***	
II	9	1	0	10	0	0	0	1	**11**	***8.5***
CSF	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*1*	***1***	
Blood	*9*	*1*	*0*	*10*	*0*	*0*	*0*	*0*	***10***	
III	60	19	1	80	0	0	0	0	**80**	***62.0***
CSF	*15*	*3*	*0*	*18*	*0*	*0*	*0*	*0*	***18***	
Blood	*45*	*16*	*1*	*62*	*0*	*0*	*0*	*0*	***62***	
IV	2	0	0	2	0	0	0	0	**2**	***1.5***
CSF	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	***0***	
Blood	*2*	*0*	*0*	*2*	*0*	*0*	*0*	*0*	***2***	
V	7	3	0	10	0	0	0	0	**10**	***7.8***
CSF	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	***0***	
Blood	*7*	*3*	*0*	*10*	*0*	*0*	*0*	*0*	***10***	
VII	1	0	0	1	0	0	0	0	**1**	***0.8***
CSF	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	***0***	
Blood	*1*	*0*	*0*	*1*	*0*	*0*	*0*	*0*	***1***	
IX	0	2	0	2	0	0	0	0	**2**	***1.6***
CSF	*0*	*0*	*0*	*0*	*0*	*0*	*0*	*0*	***0***	
Blood	*0*	*2*	*0*	*2*	*0*	*0*	*0*	*0*	***2***	
Total	**99**	**27**	**1**	**127**	**0**	**0**	**0**	**2**	**129**	***100.0***
CSF	***17***	***3***	***0***	***20***	***0***	***0***	***0***	***2***	***22***	***17.1***
Blood	***82***	***24***	***1***	***107***	***0***	***0***	***0***	***0***	***107***	***82.9***
%	***76.7***	***20.9***	***0.8***	***98.4***	***0***	***0***	***0***	***1.6***	***100.0***	



Figure 8.2 *Distribution of S. agalactiae serotypes, 2015 - 2020*

9 LISTERIA MONOCYTOGENES

Eighty-one *Listeria monocytogenes*[9] isolates were submitted to the NRLBM. Of these, 11 (14%) were from CSF (or CSF and blood) and 70 (86%) from blood only (Figure 9.1). The large majority (93%) occurred among individuals over 50 years of age (Table 9.1). Similar to previous years, serotypes 1/2a and 4b were most prevalent in 2020 (Table 9.1). The distribution of serotypes is similar to previous years (Figure 9.2)



Figure 9.1 *Number of L. monocytogenes isolates grouped by isolation source, 2011-2020*

[9] RIVM. (Dutch article) *Vleeswaren waarschijnlijk bron 20 patiënten met Listeria*. RIVM: https://www.rivm.nl/nieuws/vleeswaren-waarschijnlijk-bron-20-patienten-met-listeria

Table 9.1 Total number of *L. monocytogenes* isolates from CSF and/or blood grouped according to age of patient and serotype, 2020

	AGE (YEARS)					TOTAL	
Group	**0-4**	**5-19**	**20-49**	**50-79**	**≥80**	**T**	**%**
1/2a	0	0	3	20	7	**30**	***37.0***
CSF	*0*	*0*	*1*	*1*	*2*	***4***	
Blood	*0*	*0*	*2*	*19*	*5*	***26***	
1/2b	0	0	0	3	3	**6**	***7.4***
CSF	*0*	*0*	*0*	*0*	*0*	***0***	
Blood	*0*	*0*	*0*	*3*	*3*	***6***	
4b	0	0	3	22	20	**45**	***55.6***
CSF	*0*	*0*	*1*	*2*	*4*	***7***	
Blood	*0*	*0*	*2*	*20*	*16*	***38***	
Total	**0**	**0**	**6**	**45**	**30**	**81**	***100.0***
CSF	***0***	***0***	***2***	***3***	***6***	***11***	***13.6***
Blood	***0***	***0***	***4***	***42***	***24***	***70***	***86.4***
%	***0***	***0***	***7.4***	***55.6***	***37.0***	***100.0***	



Figure 9.2 *Percentage of L. monocytogenes isolates grouped by serotype, 2016-2020*

10 STREPTOCOCCUS PYOGENES – (group A)

Until 2019, the NRLBM received *Streptococcus pyogenes* isolates associated with meningitis only. From April 2019, the NRLBM also receives *S. pyogenes* isolates from other invasive infections (iGAS) that are submitted through 9 sentinel laboratories that cover approximately 25% of the Dutch population. In addition, the NRLBM participated in a 2-year pilot study to gain insight into puerperal sepsis/fever caused by *S. pyogenes* at the national level (pGAS) starting in 2019. Since 2015, all received S. pyogenes isolates are *emm*-typed by sequencing the hypervariable part of the *emm* gene (CDC – Streptococcus Laboratory)[10] which encodes the surface-expressed M protein. Currently, over 220 different *emm* genotypes are recognized. In 2014, an *emm*-cluster based system was proposed, clustering related M proteins based on shared binding and functional properties (Sandersom-Smith, 2014)[11].

In 2020, 180 *S. pyogenes* isolates were submitted to the NRLBM, 5 isolated from CSF (or CSF and blood; 2.8%), 112 from blood only (62.2%) and 63 from other sites (35%; Table 10.1). Almost 90% of *S. pyogenes* infections occurred in patients above the age of 20 years. The *emm* typing and *emm*-cluster based data of all isolates is displayed in Table 10.2. Over 50% of isolates belonged to *emm*-clusters E4 and A-C3 (table 10.2), with predominant *emm* types within these clusters being *emm*89 and *emm*1.0, respectively. Six isolates were submitted as Group A *Streptococcus* but turned out to be *S. dysgalactiae subsp. equisimilis* carrying the Group A antigen, a phenomenon that has been described previously.

Table 10.1 *S. pyogenes* isolates from CSF and/or blood according to patient's age, 2020.

TYPE	AGE (YEARS)					TOTAL	
	0-4	5-9	10-19	20-49	≥50	T	%
CSF	2	1	0	1	1	**5**	***2.8***
No studie	2	1	0	1	1	**5**	
pGAS	0	0	0	0	0	**0**	
iGAS	0	0	0	0	0	**0**	
Blood	7	3	2	30	70	**112**	***62.2***
No studie	3	1		10	25	**39**	
pGAS	0	0	0	9	2	**11**	
iGAS	4	2	2	11	43	**62**	
Other	1	1	1	56	4	**63**	***35.0***
No studie	1	0	1	2	1	**5**	
pGAS	0	0	0	47	0	**47**	
iGAS	0	1	0	7	3	**11**	
Total	**10**	**5**	**3**	**87**	**75**	**180**	***100***
%	***5.6***	***2.8***	***1.7***	***48.3***	***41.6***	***100***	

[10] CDC - Streptococcus Laboratory. Centers for Disease Control and Infections: https://www.cdc.gov/streplab/groupa-strep/resources.html

[11] Sanderson-Smith, M. D. (2014, feb 10). A systematic and functional classification of Streptococcus pyogenen that serves as a new tool for molecular typing and vaccine development. *J Infect Dis 210, 1325-1338*.

Table 10.2 *emm*-type and *emm*-cluster distribution of *S. pyogenes* isolates, 2020

Cluster	*emm* type	CSF	Blood	Other*	*1*	*2*	*3*	*4*	Total	%T
E1		**0**	**4**	**7**	***1***	***0***	***4***	***2***	**11**	**6.1**
	4.0	0	4	7	*1*	*0*	*4*	*2*	11	
E2		**0**	**5**	**1**	***0***	***0***	***0***	***1***	**6**	**3.3**
	76.0	0	2	0	*0*	*0*	*0*	*0*	2	
	76.13	0	2	0	*0*	*0*	*0*	*0*	2	
	76.17	0	1	1	*0*	*0*	*0*	*1*	2	
E3		**0**	**12**	**8**	***1***	***1***	***6***	***0***	**20**	**11.1**
	9.0	0	0	1	*1*	*0*	*0*	*0*	1	
	44.0	0	3	1	*0*	*0*	*1*	*0*	4	
	87.0	0	9	6	*0*	*1*	*5*	*0*	15	
E4		**1**	**23**	**22**	***1***	***0***	***18***	***3***	**46**	**26.7**
	2.0	0	1	1	*0*	*0*	*1*	*0*	2	
	22.0	0	6	4	*0*	*0*	*3*	*1*	10	
	28.0	0	5	4	*0*	*0*	*3*	*1*	9	
	77.0	0	2	4	*0*	*0*	*4*	*0*	6	
	89.0	1	9	9	*1*	*0*	*8*	*0*	19	
	89.42	0	0	1	*0*	*0*	*0*	*1*	1	
E6		**0**	**14**	**7**	***0***	***0***	***5***	***1***	**21**	**11.1**
	11.0	0	4	1	*0*	*0*	*1*	*0*	5	
	75.0	0	6	6	*0*	*0*	*5*	*1*	12	
	81.0	0	1	0	*0*	*0*	*0*	*0*	1	
	81.5	0	1	0	*0*	*0*	*0*	*0*	1	
	85.0	0	1	0	*0*	*0*	*0*	*0*	1	
	94.1	0	1	0	*0*	*0*	*0*	*0*	1	
A-C3		**3**	**32**	**9**	***1***	***1***	***5***	***2***	**44**	**24.4**
	1.0	2	29	6	*0*	*1*	*3*	*2*	37	
	1.3	0	0	1	*0*	*0*	*1*	*0*	1	
	1.19	1	0	0	*0*	*0*	*0*	*0*	1	
	1.25	0	2	0	*0*	*0*	*0*	*0*	2	
	1.87	0	0	1	*0*	*0*	*1*	*0*	1	
	1.100	0	1	0	*0*	*0*	*0*	*0*	1	
	1.134	0	0	1	*1*	*0*	*0*	*0*	1	
A-C4		**1**	**10**	**7**	***0***	***2***	***5***	***0***	**18**	**10.0**
	12.0	1	7	4	*0*	*1*	*3*	*0*	12	
	12.32	0	0	1	*0*	*1*	*0*	*0*	1	
	12.37	0	3	2	*0*	*0*	*2*	*0*	5	
A-C5		**0**	**4**	**0**	***0***	***0***	***0***	***0***	**4**	**2.2**
	3.93	0	4	0	*0*	*0*	*0*	*0*	4	
M		**0**	**7**	**1**	***0***	***0***	***1***	***0***	**8**	**4.4**
M5	5.23	0	1	0	*0*	*0*	*0*	*0*	1	
M6	6.0	0	3	1	*0*	*0*	*1*	*0*	4	
	6.4	0	1	0	*0*	*0*	*0*	*0*	1	
M14	14.3	0	1	0	*0*	*0*	*0*	*0*	1	
M74	74.0	0	1	0	*0*	*0*	*0*	*0*	1	
Other		**0**	**1**	**0**	***0***	***0***	***0***	***0***	**1**	**0.6**
	264.0	0	1	0	*0*	*0*	*0*	*0*	1	
Total		**5**	**112**	**63**	*4*	*4*	*46*	*9*	**180**	

*1: abscess; 2: Throat, nose, ear, BAL, sputum; 3: Cervix, fluor, vagina, lochia, urine; 4: Synovial fluid, wound

11 ANTIGEN AND DNA DETECTION

The NRLBM received 99 culture-negative specimens of CSF, serum or other bodily fluids for antigen or DNA detection (Table 2.1). Lateral Flow Assay for cryptoccal antigen (LFA assay) was used to detect *C. neoformans*. PCR was performed with primers and probes specific for *N. meningitidis* (targeting *ctrA*) for *S. pneumoniae* (targeting *pia*) and for *H. influenzae* (*siaT* gene). When CSF was positive in the meningococcal PCR, the same sample was subjected to serogroup-specific PCR.

Of 99 culture-negative samples, 25 (34%) were positive for one of the target species by PCR or LFA test. Of these, 14 (56%) (12 CSF, 2 sera) were positive for *N. meningitidis*, 7 (28%) were positive for *S. pneumoniae* and 2 (8%) were positive for *H. influenzae*.

Table 11.1 CSF and serum samples tested for antigens or DNA, 2020

	CSF * (or DNA from CSF)	SERA or other fluids	TOTAL
***C. neoformans* (LFA)**	2	0	**2**
DNA of			
N. meningitidis group B	10	0	**10**
N. meningitidis group W	2	0	**2**
N. meningitidis groep C	0	1	**1**
N. meningitidis groep Y	0	1	**1**
S. pneumoniae	7	0	7
H. influenzae	2	0	2
Sub Total	**23**	**2**	**25**
Antigen and PCR negative	65	9	**74**
Total	**88**	**11**	**99**

*From 7 patients with *S. pneumoniae* isolated from blood, the CSF was culture-negative but PCR-positive for pneumococcal DNA. Those were counted as CSF patients.
From 12 patients with *N. meningitidis* isolated from blood, the CSF was culture-negative but PCR-positive for meningococcal DNA. Those were counted as CSF patients.
In 2 patients DNA of *N. meningitis* was detected in urine and pus
Of all 2 patients with positive Hi PCR a blood isolate was received. Those patients were counted as CSF patients.
The 9 fluids other than CSF were from sera, a biopsy and pericardial fluid

12 PUBLICATIONS

1. Rumke LW, de Gier B, Vestjens SMT, van der Ende A, van Sorge NM, Vlaminckx BJM, Witteveen S, van Santen M, Schoulds LM, Kuijper EJ. Dominance of M1UK clade among Dutch M1 *Streptococcus pyogenes*. **Lancet Infect Dis**. 2020 May; 20 (5): 539-540. doi: 10.1016/S1473-3099(20)30278-4

2. Garcia Garrido HM, Mak AMR, Wit FWNM, Wong GWM, Knol MJ, Vollaard A, Tanck MWT, van der Ende A, Grobusch MP, Goorhuis A. Incidence and Risk Factors for Invasive Pneumococcal Disease and Community-acquired Pneumonia in Human Immunodeficiency Virus-Infected Individuals in a High-income Setting. **Clin Infect Dis**. 2020 Jun 24; 71 (1): 41-50. doi: 10.1093/cid/ciz728

3. Loenenbach AD, van der Ende A, de Melker HE, Sanders EAM, Knol MJ. The clinical picture and severity of invasive meningococcal disease serogroup W compared with other serogroups in the Netherlands, 2015-2018. **Clin Infect Dis**. May 6; 70 (10): 2036-2044. doi: 10.1093/cid/ciz578

4. Jamrozy D, Bijlsma MW, de Goffau MC, van de Beek D, Kuijpers TW, Parkhill J, van der Ende A, Bentley SD. Increasing incidence of group B *Streptococcus* neonatal infections in the Netherlands is associated with clonal expansion of CC17 and CC23. **Sci Rep** 2020 Jun 12; 10 (1): 9539. doi: 10.1038/s41598-020-66214-3

5. Freudenburg-de Graaf W, Knol MJ, van der Ende A. Predicted coverage by 4CMenB vaccine against invasive meningococcal disease cases in the Netherlands. **Vaccine** 2020 Nov 17; 38 (49): 7850-7857. doi: 10.1016/j.vaccine.2020.10.008

6. Figueiredo AHA, Brouwer MC, Bijlsma MW, van der Ende A, van de Beek D. Community-acquired pneumonia in patients with bacterial meningitis: a prospective nationwide cohort study. **Clin Microbiol Infect** 2020 Apr; 26 (4): 512.e7-513.e11. doi: 10.1016/j.cmi.2019.09.001

7. Kremer PHC, Lees JA, Ferwerda B, Bijlsma MW, MacAlasdair N, van der Ende A, Brouwer MC, Bentley SD, van de Beek D. Diversification in immunogenicity genes cause by selective pressures in invasive meningococci. **Microb Genom**. 2020 Sep; 6 (9): mgen000422. doi: 10.1099/mgen.0.000422

8. Ter Horst L, Brouwer MC, van der Ende A, van de Beek D. Community-acquired bacterial meningitis in adults with cerebrospinal fluid leakage. **Clin Infect Dis** 2020 may 23; 70 (11): 2256-2261. doi: 10.1093/cid/ciz649

9. Rodgers E, Bentley SD, Borrow R, Bratcher HB, Brisse S, Brueggemann AB, Caugant DA, Findlow J, Fox L, Glennie L, Harrison LH, Harrison OB, Heyderman RS, van Rensburg MJ, Jolley KA, Kwambana-Adams B, Ladhani S, LaForce M, Levin M, Lucidarme J, MacAlasdair N, Maclennan J, Maiden MCJ, Maynard-Smith L, Muzzi A, Oster P, Rodrigues CMC, Ronveaux O, Serino L, Smith V, van der Ende A, Vázquez J, Wang X, Yezli S, Stuart JM. The global meningitis genome partnership. **J Infect** 2020 Oct; 81 (4): 510-520. doi: 10.1016/j.jinf.2020.06.064

10. Koelman DLH, van Kassel MN, Bijlsma MW, Brouwer MC, van de Beek D, van der Ende A. Changing Epidemiology of Bacterial Meningitis Since Introduction of Conjugate

Vaccines: Three Decades of National Meningitis Surveillance in The Netherlands. **Clin Infect Dis** 2020 Nov 28; ciaa1774. doi: 10.1093/cid/ciaa1774

11. Ter Horst L, Brouwer MC, van der Ende A, van de Beek D. Recurrent community-acquired bacterial meningitis in adults. **Clin Infect Dis** 2020 Oct 9: ciaa1623**.** doi: 10.1093/cid/ciaa1623

13 ACKNOWLEDGEMENTS

Many have contributed to the work of the NRLBM and to this report. We would like to thank:

- the National Institute of Public Health and the Environment (RIVM Bilthoven. dr. J.T. van Dissel) for ongoing financial support and scientific interaction (Dr. Mirjam Knol).
- Mrs. A. Arends. Mrs. W.C.M Bril - Keijzers. Mrs. M.M. Feller and Mrs. I.G.A. de Beer for their outstanding technical laboratory assistance
- Mrs. I.G.A. de Beer for preparing data from the computer files and layout of this report